









Title of Document: DEFINING CRITICAL PARAMETERS FOR PRODUCING AND 
MODULATING INFLAMMATION CAUSED BY CELL 
ENCAPSULATING ALGINATE MICROSPHERES 
  
 Joyce Catherine Breger, Master of Science, 2007 
  
Directed By: Associate Professor Nam Sun Wang 
Department of Chemical and Bimolecular Engineering 
 
Minimizing induced inflammation, particularly nitric oxide (NO) production, is 
critical to optimal function or failure of implanted encapsulated cells.  The purpose of 
this study is to define critical factors that affect toxic NO production from the 
macrophage cell line RAW264.7 in response to alginate microcapsules.  The effects 
of the following were determined: 1) concentration of endotoxin (LPS) 
contamination; 2) presence of interferon-gamma (IFN-γ); 3) bead diameter and 
alginate volume; and 4) anti-inflammatory drugs in the alginate.  A higher 
concentration (5 X) of LPS was required in alginate to produce the effect seen by LPS 
free in medium, sensitivity was enhanced by IFN-γ, bead diameter was inversely 
proportional to NO2 under low inflammatory conditions, and parthenolide in alginate 
significantly reduced inflammation.  These results suggest that survival of implanted 
encapsulated cells may be improved by using highly purified alginate, avoiding 
ancillary inflammation, controlling surface area presentation, and incorporating anti-
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Chapter 1: Introduction 
 
1.1 Introduction 
This thesis is divided into six chapters. The first chapter provides a brief 
introduction to the thesis as well as a literature review. In the second chapter, 
background is given on each of the main components that are common themes in each 
of the preceding chapters. Chapters 3 through 5 each represent a study that addresses 
a goal of the thesis. At the beginning of each of these chapters is a more detailed 
introduction and background to the themes that are specific to that study. The third 
chapter determines the No Observable Effect Level (NOEL) of 2% w/v alginate in 
stimulating nitric oxide (NO) production by the cell line RAW264.7 by comparing 
free LPS to LPS incorporated into 2% w/v Pronova alginate. This was also done in 
the presence of IFN-γ to compare simple to more complex inflammatory responses. 
After establishing what levels of endotoxin could be present that did not stimulate a 
significant increase in NO2 concentration compared to the control (NOEL), the effect 
of bead size on NO production of RAW264.7 was explored in Chapter 4. The last 
study, Chapter 5, explores the possibility of modulating NO production by 
RAW264.7 by incorporating inflammatory modulators directly into the alginate bead. 
Finally, Chapter 6 draws together all of the conclusions that were found in each 




1.2 Bioassays for Contamination 
1.2.1 Alginate Purification Method 
The development of the bioartifical pancreas is being hindered by the many 
things such as alginate contamination. Alginate is currently harvested from seaweed 
and as such the composition is highly variable, along with the amount of 
contamination present from lot to lot. The three main types of contamination are 
endotoxin, polyphenols, and proteins (Dusseault et al. 2005). Contamination is a very 
important consideration given the extreme difficulty and expense in removing it 
during processing. Trace amounts of contamination can lead to aggravated 
inflammatory responses by the host which can lead to graft failure. The main strategy 
for trying to minimize the problem is removing contamination to the lowest 
concentration possible, and then carefully defining what remains. Leinfelder et al. 
(2003) developed an assay for the validation of purification regimes of alginate. The 
assay is based on using the Jurkat cell line and measuring the induction of apoptosis. 
They also used a proliferation assay to study lymphocytes’ response to different 
alginate lots. The two assays rely on determining the ratio of dead cells/debris to 
viable proliferating cells and the use of trypan blue along with flow cytometry 
respectively (Leinfelder et al. 2003).  
 The two cell lines did react in a dose dependent manner to the various types of 
contamination and were able to detect endotoxin concentrations of <2.5 EU/mL. 
These results were confirmed by doing histological analysis of implanted alginate 
microcapsules in diabetic BB rats and determining the level of fibrosis. Therefore 




contamination in biomaterials such as alginate, and be predictive of in vivo 
inflammation related adverse effects. 
1.2.2 RAW264.7 Reacts to LPS and INF-γ 
A study performed by Kim, Y.M. et al. (1996) developed a nitric oxide 
bioassay for the detection of IFN-γ. The assay was developed as a simple, 
inexpensive, and specific alternative to the ELISA and RIA assays. The colorimetric 
assay employed the RAW264.7 cell line to test for IFN-γ bioreactivity and was able 
to distinguish IFN-γ from other types of interferons. They also showed that RAW 
cells produced 2.5 to 3.5 times more NO in the presence of lipopolysaccharide (LPS) 
and IFN-γ than in the presence of either one alone. There was a linear correlation 
between NO production and low concentrations of IFN-γ (0-10 EU/mL) and 
logarithmic dependence at concentrations of 2-100 EU/mL. Other benefits to the 
assay were that it relatively rapidly yielded results after only 16 h, ease of adding 
colorimetric reagents (Griess reagent) to the medium for detection, inexpensive, 
nonradioactive, nonviral, and reproducible. (Kim et al. 1996) 
Morphological and growth changes occur to macrophages when in the 
presence of certain stimuli. Zhuang et al. (1997) showed that the growth and viability 
of RAW was effected when continuously stimulated up to 23 days with LPS and/or 
IFN-γ. When exposed to either LPS or IFN-γ, the doubling times increased to 2-4 
times the rate of unstimulated RAW cells. However, once either stimulant was 
removed, 24 h later the exponential growth rate returned. After LPS and IFN-γ were 




exponential growth rate to return. RAW cells are capable of producing NO over 
extended periods of time when in the presence of stimuli, are resistant to its deadly 
effects, and are an excellent model system to study nitric oxide mediated 
inflammatory progress. (Zhuang et al. 1997) 
 
1.3 Modulating Agents of RAW264.7 
1.3.1 Introduction 
Pancreatic islets are known to be sensitive to the toxic effects of macrophage-
mediated nitric oxide due to low expression of antioxidant enzymes (Chae et al. 
2004). There are very few studies where investigators have tried to incorporate 
modulating agents into alginate for the purpose of mitigating NO production. One 
such study performed by Chae et al. (2004) coencapsulated hemoglobin cross linked 
(Hb-C) with poly(ethylene glycol) with rat islets or insulinoma cells into 
alginate/poly(L-lysine)/alginate microcapsules. Hemoglobin acts as a NO scavenger 
and given NO’s small molecular size, it can easily diffuse through alginate and react 
with hemoglobin forming nitrosylhemoglobin or methemglobin which is non-lethal to 
islets. A nitric oxide donor, S-nitroso-N-acetylpenicillamine (SNAP), was added to 
culture medium to generate varying concentrations of NO. The cellular viability along 
with insulin secretion was measured for two groups: the control which encapsulated 
islets contained no Hb-C or SNAP and encapsulated islets with Hb-C and SNAP. 
Indeed, islets coencapsulated with Hb-C had higher viabilities, insulin secretion 




control. Encapsulated islets with no Hb-C exposed to SNAP showed concentration 
dependent cellular damage and apoptosis. Although NO scavengers such as Hb-C 
may be useful for acute NO scavenging in alginate capsules, chronic or high levels of 




Other researchers have developed protocols that are used before encapsulated 
islets are transplanted into the body to try to reduce the numbers of reactive cells in 
advance of implantation. These preparation methods rely on removing the majority of 
macrophages already present to limit the production of NO before graft implantation. 
Bisphosphonates are most commonly used in the treatment of bone disease but have 
begun being studied in treatment of other inflammatory diseases. In one study 
performed by Monkkonen (1994), three types of bisphosphonates (clondronate, 
pamidronate, and etidronate) were studied using different preparations to inhibit 
growth of RAW264.7 and CV1-P. All three bisphosphonates were prepared 
separately in either liposomes, free in solution, or bound to calcium. Each of these 
preparations was then added to RAW264.7 or CV1-P and cultured for up to 72 h. 
Cellular growth was then evaluated using the MTT-assay. All three drugs that were 
encapsulated into liposomes significantly inhibited RAW264.7 and CV1-P growth; 
while the drugs free in solution were 20-1000 times less effective. The presence of 
high extracellular calcium increased the potency of all three bisphosphonates. 




Bisphosphonates encapsulated into liposomes were used by Omer et al. 
(2003) as a preparatory treatment before transplanting encapsulated islets into the 
peritoneal of rats. The goal was to deplete the macrophage population present to 
extend the biocompatibility and function of encapsulated islets. Liposomes containing 
clondronate or saline was injected into the peritoneal cavity of normoglycemic Lewis 
rats two to five days before transplantation. Either empty PLL/alginate microcapsules 
or encapsulated neonatal porcine islets were then placed in the cavity. The insulin 
response and surrounding macrophage population was studied. When the cavity was 
just flushed with saline prior to transplantation, the empty and especially the islet 
containing microcapsules were overgrown with macrophages. However, when the 
cavity was flushed with the clondronate solution the empty capsules had no 
macrophage overgrowth while the encapsulated islets had much less macrophage 
overgrowth and a higher insulin response when compared to the control.  These two 
studies show that bisphosphonate is effective in decreasing NO production by 
macrophages and can increase the lifespan of encapsulated islets. However, studies 
incorporating free or liposome-contained bisphosphonates directly into alginate have 
not been done yet. 
 
1.3.3 Parthenolide 
Parthenolide is a potent anti-inflammatory known to inhibit the NF-κB 
pathway, the main inflammatory pathway, by targeting IκB kinase.  A study by Kang 




production by RAW264.7 in a dose dependent manner through affecting the NF-κB 
binding site in the p40 promoter region. 
Another study (Yip et al. 2004) explored the parthenolide mechanism further 
by inducing RAW264.7 to differentiate into osteoclasts and then stimulated them with 
LPS. Parthenolide was used as a possible inhibitor of LPS-induced osteolysis. The 
study showed when parthenolide was injected along with LPS into mice it blocked 
osteolysis. Other assays for NF-κB activation, p65 translocation, and IκB-α 
degradation were used to determine parthenolide’s mechanism in osteoclasts. 
Parthenolide was shown to inhibit all three leading to the confirmation that 
parthenolide inhibits the NF-κB pathway. Overall, parthenolide has been shown to be 
a potent inhibitor of RAW264.7 production of NO in our lab and in others. Studies 
testing parthenolide’s inflammation-inhibiting characteristics when directly 
incorporated into a biomaterial have not been done yet.  
 
1.4 Summary 
Though well studied for other endpoints, RAW264.7 has not been employed 
as an assay technique for determining LPS contamination levels in alginate capsules. 
Using RAW264.7 as a generator of inflammatory mediators such as nitric oxide 
determined by colorimetric assay could be a very powerful biological tool for 
detecting low levels of LPS contamination in alginate and other biomaterials. Since 
RAW264.7 is a model macrophage cell line, the data revealed by the assay could give 




concentration and presentation of LPS in biomaterials as to the final observed 
inflammatory response. Using IFN-γ should allow for even more sensitive detection 
of LPS contamination in alginate given IFN-γ’s natural function in the body to help 
alert and amplify the body’s response to initially low levels of pathogens. 
 The use of modulating agents incorporated into alginate has rarely been 
studied to date. Given the extreme sensitivity of islets to NO and the impossibility of 
completely removing all contamination from alginate, agents incorporated into 
alginate to mitigate NO production by impinging macrophages might be a key factor 











The immune system is very complex, relying on a number of cell types and 
cellular signals to protect the host from possible infection that would lead to death. 
Therefore, creating treatments that rely on donor tissue and biomaterials (such as 
encapsulated islet cells) currently have very limited success due to a lack of 
understanding of the immune system. For the development of such a promising 
treatment that can be applied to a number of medical conditions, there needs to be a 
better grasp of the action of the immune system. The immune system is so sensitive 
that it will even react to something as infantile as a splinter in the thumb. Research 
should not only be focused on discovering ways to circumvent the immune system 
but to determine what modest level of immune reaction will not cause rapid graft 
failure. Also, a change of mindset should be considered. Instead of thinking, for 
example, that bioartifical organs will provide an ultimate cure they should be 
considered as one more tool for treatment in a chronic disease, thus providing a 
greater level of freedom for an extended period of time.   
 Below is an introduction to the basic players that effect the development of a 
bioartifical pancreas. These key concepts will enable the reader to better appreciate 
the complexity in developing new techniques in treating chronic diseases, such as 




determining what levels of nitric oxide (NO), an indicator of immune response that is 
produced by macrophages, is due to a biomaterial or to impurities such as bacterial 
endotoxin. 
 
2.2 Role of Macrophages 
2.2.1 Role of Macrophages in the Immune System 
Macrophages are derived from monocytes/white blood cells and are part of 
the “innate” immune system. The innate immune system works in conjunction with 
the “adaptive” immune system. It is so highly evolutionary conserved that not only is 
the innate immune system found in vertebrates but invertebrates and even plants. As a 
first responder to potential infections, the innate immune system uses macrophages, 
along with other cell types, to phagocytize foreign bodies, produce NO, and an 
elaborate assortment of cytokines. Whereas the adaptive immune system is slow to 
respond to a new infection while antibodies from B and T cells are synthesized, the 
innate immune system responds quickly and imprecisely. The function of 
macrophages in the innate immune system is to stimulate “inflammatory responses” 
that phagocytize foreign cells and produce cytokines. An inflammatory response is 
characterized by pain, redness, heat, and swelling (Alberts et al. 2002). Macrophages 
are something like the police force of the body, quick to respond to attack as 
compared to the justice system which comes into play preventing future crime 




To recognize a pathogen and begin the phagocytizing process, macrophages 
rely on certain proteins that are only common to pathogens; which are located on the 
cellular surface. Once encountering a pathogen and recognizing it with cell surface 
receptors, macrophages will try to engulf the pathogen completely. Then a concerted 
attack begins with the production of highly acidic species and various highly toxic 
oxygen derived compounds. Important oxygen species include superoxide (O-2), 
hypochlorite (HOCl), hydrogen peroxide (H2O2), hydroxyl radicals, and nitric oxide 
(NO) (Swindle et al. 2007). These compounds, if prevalent in the body, would cause 
instantaneous death in susceptible tissue but has little effect on macrophages. If the 
pathogen is too big for a macrophage to phagocytize it, groups of macrophages and 
other phagocytic cell types surround the pathogen and exocytose their lethal 
compounds to obliterate the pathogen. 
 
2.2.2 The Model Macrophage: RAW264.7  
A cell line commonly used in studying macrophages is RAW264. It was 
developed by Rascke et al. in 1978 using the Abelson leukemia virus. This virus 
transformed macrophages into a cancerous cell line with no detectable virus activity. 
The RAW264 cell line is a specialized subset of peritoneal macrophages possessing 
the ability of anti-tumor activity. It was shown by Raschke et al. that the RAW264 
cell line possessed all the same properties that native macrophages do; including 
taking up red dye, synthesizing and secreting lysozyme, phagocytizing latex beads, 





2.3 Role of NO 
2.3.1 NO Is A Soluble Gas 
Only recently discovered in the late 80’s (Ignarro et al. 1987; Furchgott et al. 
1989), NO has been a controversial substance in medicine and physiology. While not 
all of the myriad roles of NO have been discovered or fully understood, one thing is 
for sure: while NO may have seemingly contradictory effects in the body it is vitally 
important in the immune system, cellular signaling, neurotransmission, 
vasodilatation, inhibition of platelet aggregation, and inflammation (Ignarro 1990; 
Murad 1998; Coleman 2001). Some of the mechanisms of NO are fairly well 
understood, such as how NO causes endothelial cells to relax (Ignarro et al. 1987). 
Less well understood are how some cell types seem to be more resistant to NO 
compared to others. Within the innate immune system, the mechanism of action is 
still mysterious and sometimes contradictory. However, the overall effect of NO on 
foreign invading microbes or “innocent bystander” host cells is startlingly dramatic 
death.  
 
2.3.2 Chemistry of NO 
In the innate immune system, NO is structurally perfect for its role as stealthy 
annihilator. The small size of NO, a mere 30 Da, allows it to diffuse easily 
intracellularly and across cellular membranes due to having no specific cell surface 
receptor.  Also, NO exhibits relatively stable free radical chemistry; it has no charge 




seconds to a few hours by reversible reactions with cysteine and specialized proteins. 
These reversible reactions allow for the transportation of NO from macrophages to 
cells that might be relatively far away while keeping NO still highly reactive 
(Swindle et al. 2007).  
The effectiveness of NO is extended by being able to react with other 
compounds to form other, equally harmful substances. Under aerobic conditions, NO 
is oxidized to form reactive nitrogen oxide species (RNOS). These RNOS, once 
excreted, can be hydrolyzed to form nitrites. The detection of nitrites in the solute is 
used as an indirect method for the detection of NO production. Another major 
product, under aerobic conditions, is N2O3. Under anaerobic conditions, NO can react 
with O2- to form the peroxynitrite anion (ONOO-) which is highly toxic and mediates 
the most severe of toxic effects.  
 
2.3.3 NO Is Involved In the Innate Immune System 
In the innate immune system, NO is produced by a variety of immune cells 
such as macrophages, fibroblast, natural killer cells, etc (Alberts et al. 2002). Recent 
studies have shown that many autoimmune diseases that involve inflammation; such 
as asthma, rheumatoid arthritis, or type I diabetes, have been linked to the 
overproduction or poorly regulated production of NO. In healthy individuals, when 
NO is produced with regards to the innate immune system it is toxic to pathogens and 
regulates cellular death. In general, NO will cause apoptosis, necrosis, stimulate 





2.3.4 NO is produced by iNOS 
There are three different enzyme isoforms that produce NO in the body for 
accomplishing a variety of purposes: NOS-1 (eNOS), NOS-2 (iNOS), and NOS-3 
(nNOS). Originally named after the cell types where discovered or for function, it 
since has been determined that these isoforms are found in an assortment of cell 
types. In all three of the isoforms, NO is produced from the reaction of L-arginine 
with molecular oxygen utilizing NADPH (Weisz et al. 1994).  
 The isoforms, NOS-1 and NOS-3, are expressed constitutively. The 
expression is Ca+2 dependent, with a low level of expression, and produces NO is a 
pulse like nature; ideally suited for neurotransmission or quick cellular signaling. 
However, NOS-2 is only inducibly expressed (hence i-NOS) and is Ca+2 independent. 
The enzyme, NOS-2, is activated by LPS or cytokines. Once stimulated, the enzyme 
continuously produces sustained, high levels of NO production following a lag time 
of a few hours. The lag time occurs because necessary proteins for the enzyme must 
be synthesized from mRNA. Once there is a sufficient level of NOS-2, NO 
production can be sustained for a few hours to days. According to Weisz (1994), 
maximal mRNA concentration is achieved when macrophages have been exposed to 
a combination of LPS and interferon-γ (IFN-γ). The synergistic effect of the 
combination of LPS with IFN-γ is thought to be due to the stabilization of LPS on 







2.4 Role of LPS 
Lipopolysaccharide (LPS), also known as endotoxin, makes up part of the 
cellular wall of gram negative bacteria. Bacterium can be generally separated into two 
distinct groups: gram-positive and gram-negative bacteria. Gram-positive bacteria are 
surrounded by a cellular wall composed of peptidoglycan; a substance completely 
foreign to the human body. Therefore, the body can efficiently attack and destroy 
gram-positive bacteria. However, gram-negative bacteria, in general, have a more 
robust cellular wall, a capsule, and are covered in a layer of slime that inhibits the 
immune system from recognizing antigens present on the cellular wall. These 
structural differences in cellular wall composition are the basis for distinction 
between gram-negative and gram-positive bacteria (Alberts et al. 2002). It is 
important to note that this classification system is completely empirical and there are 
many types of bacteria that fall in both or neither category. 
 For LPS to activate macrophages it must first bind to “LPS binding protein” 
found in blood, which then binds to the CD14 receptor on the macrophage cell 
surface which instigates a cascade of reactions ultimately concluding in the binding to 
Nuclear Factor-Kappa B (NF-κB) to DNA. The transcription factor NF-κB, 
specifically associated with the innate immune response and inflammation, causes the 
up regulation of genes leading to increased production of such chemicals as NO and 





2.5 Role of a Cytokine 
Cytokines play an important role in our body mainly as a means of amplifying 
an immune response. They are similar to hormones in that they are considered 
signaling compounds. However, they differ from hormones in that they are not 
produced by specific organs but by many different cell types. Some of the cytokines 
involved in immune response include interferons, interleukins, TGF-β,  and TNF-
α.  Cytokines work by binding to specific cytokine receptors and setting off a cascade 
of events that lead to significant up regulation or down regulation of specific cellular 
products. Cytokines are used by macrophages to alert other immune cell types, 
stimulation activation, and increased phagocytic activity.  
 
2.5.1 Interferon-γ 
In this thesis, IFN-γ is used as a model cytokine to better understand complex 
immune reactions and the effect on NO production by RAW264.7 in the presence of 
LPS. It also increases phagocytic activity, which was not studied here. The cytokine 
IFN-γ can be produced by neighboring cell types such as T and/or B cells or by 
macrophages themselves. Cytokines, such as IFN-γ, act as chemoattractants, signaling 
other immune cell types that there is a pathogen and to respond. Besides altering the 
function of other immune cell types, IFN-γ, causes more NO production in 





2.6 Description of Alginate 
Alginate is a very common biomaterial used in an assortment of industrial 
products and as medical treatments. As far back as the 18th century, there has been 
documentation of the health benefits and usefulness of alginate. Formally discovered 
in 1883 by E.E.C Stanford, a whole number of industries exploded on to the scene as 
the result of manufacturing alginate/alginc acid from brown seaweed. Besides food 
consumption, alginate was used in the manufacture of soda ash, glass, and for 
nutritional iodine. Alginate is still in the thick of it by currently being very popular in 
the pharmaceutical industry. Pharmaceutical alginate is used in sustained/controlled 
release drugs, wound healing dressings, blockage of esophageal /oesophageal reflux, 
and as a matrix in tissue engineering. (Myrvold et al. 2004) 
The popularity of using alginate in a variety of medical applications is due in 
part to the fact that it is one of the few materials that can gel at physiological 
conditions. This property is currently very rare among biomaterials; as most are 
gelled using harsh chemicals and under non-physiological conditions. Currently, most 
alginate is still being produced from brown seaweed. In seaweed, alginate’s role is to 
provide structural support and flexibility; two features of importance in many desired 
tissue engineered products. Other sources of alginate are the two types of soil 
bacteria, Azotobacter vinelandil and Psesudomons. The main disadvantage of alginate 
compared to other commercially available biomaterials is that the purity and chemical 
composition can vary considerably from lot to lot. Also, chemical homogeneity can 





2.6.1 Chemical Composition of Alginate 
Alginate is a polysaccharide made of β-D-mannuronate (M) and α-L-
guluronate (G) units (Fig. 1) that can form common block patterns such as GG, MM, 
GM, MG through the formation of 1 4 glycosidic bonds. The amount or number of 
GG blocks is believed to be one of the leading factors in determining gel strength. 
This is due to the unique cavity structure that is formed when two G monomers 
common together causing divalent cations, such as Ca+2, to preferentially bind over 
other block patterns (Fig. 2). When many GG blocks are strung together and are in 
the presence of a divalent cation, an “egg-box model” structure (Fig. 3), appears 
creating a mesh network that is suitable for immunoisolation or other tissue 
engineering projects.   
 
Figure 1. The Two Monomers, β-D-Mannuronate and α-L-Guluronate (G). These 
monomers can be randomly arranged to form linear block patterns such as MM, GG, 
MG, and GM. (Myrvold et al. 2004) 
 
Figure 2. A Calcium Ion Binding In a Pocket Formed by Two Di-axially Linked G 




   
Figure 3. Schematic Showing Linearly Arranged M and G Units and the Effect of 
Adding a Divalent Cation, Such as Calcium. A mesh network is formed allowing for 
the flow of nutrients, waste removal, and products while providing an effective 
barrier to cells and molecules of the immune system.(Myrvold et al. 2004) 
 
The ideal chemical composition of alginate is in contentious debate. It might 
be a mute point since most commercially available alginate is derived from the fickle 
brown seaweed. In regards to tissue engineering, the concern is the ratio of M/G 
blocks on rigidity and the effect on excluding immune components. Alginate 
containing a high amount of guluronate is more brittle and has a higher permeability 
to antibodies. Simply having grown in rough waters can cause brown seaweed to have 
a higher amount of guluronate. On the flipside, having a greater amount of 
mannuronate present makes the alginate more flexible and less permeable. Any 
divalent cation can bind preferentially to the GG blocks but depending on the cation 
there is a difference in gel strength. The gel strength of alginate increases as follows: 
Mn+2 <Co+2 <Ni+2 <Zn+2 <Ca+2 <Sr+2 <Ba+2 <Cd+2 <Cu+2 <Pb+2 (Morch et al. 2006). 
However, calcium remains the popular choice for gelation since it is readily found in 
the body and is non-toxic. The other two most commonly used gelation ions are 
Barium and Strontium. These are not widely used for gelation of alginate due to 





There has been some debate about whether the ratio of M to G has an effect of 
the immune response (Otterlei et al. 1991; Klock et al. 1997; Orive et al. 2004), but 
this has since been put to rest due to better purification processes to get rid of 
contaminants. Types of contaminants that can themselves cause immune responses 
include: proteins, complex carbohydrates, fatty acids, phospholipids, toxins, 
polyphenols, and the ubiquitous endotoxin (LPS). Endotoxin is thought to be the 
culprit for most of the immune response seen to alginate. 
 
2.7 Definition of Risk Assessment Parameters 
In toxicology, risk assessment is used to determine acceptable levels of 
exposure to chemical agents in human health and ecology (Eason et al. 2002). In the 
case of human health, toxicological studies use animal and in vitro studies to 
determine acceptable concentration levels and lengths of exposure to suspected 
chemical agents. These data are then extrapolated to the human case and are used in 
regulatory decisions. In the case of ecology, this same type of paradigm is used in 
recognizing pollutants in the air, water, and the effects on wild life. The idea is that in 
a highly controlled experimental environment specific chemical agents can be more 
easily identified and assessed. However, one obvious disadvantage is that rarely do 








2.7.1 Types of Risk Assessment Parameters 
Traditionally, there have been a number of terms used to quantify the 
observable effects of chemical agents seen in toxicology such as LD50 (Lethal Dose, 
50 %, the dose that kills 50% of the population), benchmark method, etc.  To 
encapsulate either positive or negative observations, two other terms have been in 
vogue; the “No Observable Effect(s) Level” (NOEL) and the associated “Lowest 
Observable Effect(s) Level” (LOEL) (Haag-Gronlund et al. 1995). These terms are 
used in regulatory risk assessment of potential drugs, combination devices, or other 
materials/chemical that are suspected to cause an effect. Such regulatory terms are 
used in the assessment of experiments done with model animal specimens or in vitro 
models for the purposes of extrapolation to potential human side effects.    
 In the simplest of terms, if an experiment was conducted to elucidate the level 
of drug required to cause no significant change between it and a control that would be 
considered the NOEL, whether the chemical response was stimulatory or inhibitory. 
The very next higher concentration or dose of chemical would be considered the 
LOEL because it would be the lowest observable data point that was significantly 
different from the control. In layman terms, the NOEL would be “How Much Is Not 
Enough” to cause a response and the LOEL would be “How Much Is Just Enough” to 
cause a response.  
 For this thesis, the NOEL and LOEL were determined for a variety of 
conditions in the presence of RAW264.7 and LPS as a way to elucidate the effect of 




from patient to patient, and from experiment to experiment the NOEL and LOEL are 
not absolutely fixed quantities, but can change slightly due to systematic fluctuations.  
2.8 NO and Islets of Langerhans 
Islets of Langerhans are a unique cell type found in the pancreas. Their main 
job is to produce insulin in the regulation of glucose homeostasis. Insulin is also 
important in the regulation of a myriad of different bodily functions, making the loss 
of insulin production profoundly detrimental. As mentioned earlier, type I diabetes is 
an autoimmune disease that causes the destruction of β-cells and hence stops insulin 
production. The disease, unfortunately, is often only diagnosed once the majority of 
the islets have been irrevocably destroyed. 
2.8.1 Current Treatments of Type I Diabetes 
Current treatments rely on constant blood glucose monitoring and insulin 
injections. This situation is not ideal since insulin in the body is produced at a more 
continuous level and there may be severe side effects if insulin is incorrectly injected 
when the patient is hypoglycemic. In extreme cases, death or coma can occur. This 
has driven research aimed at coming up with novel solutions for the treatment of type 
I diabetes.  Transplantation of panaceas’ or islets has had limited success partially 
because islets are extremely sensitive and the necessary immunosuppressive drug 
regime may cause their premature death (Couzin 2004). This has encouraged 
investigators to explore creating a bioartificial pancreas. The bioartificial pancreas 
uses a biomaterial, such as alginate, to encapsulate donor islets before transplantation. 




dramatically reducing or eliminating the need for immunosuppressive drugs, and 
consequently prolonging donor tissue survival.  
2.8.2 NO Hinders Development of Bioartificial Pancreas 
In this thesis, the production of NO is used as an indicator of inflammation 
and immune response which hinders the development of a bioartificial pancreas 
(Kroncke et al. 1993; Wiegand et al. 1993; Suarez-Pinzon et al. 1994; Kaneto et al. 
1995) (Fig.4). The concern is that since NO is such a small compound it can easily 
diffuse through alginate and cause the cessation of insulin production by the islets of 
Langerhans. The biomaterial used in any encapsulation technique is required to allow 
the diffusion of oxygen, nutrients, chemical signals, etc. into the gel while also 
allowing diffusion of waste and cellular products out of the gel (De Vos et al. 2002). 
It would be highly improbable to create a biomaterial that will prevent the diffusion 
of NO without sacrificing the diffusion of these other requirements. Therefore, a 
concerted effort is underway to better understand the immune response to 




















Figure 4. How Macrophages Can Effect the Development of the Bioartifical 
Pancreas. Macrophages produce a number of cytotoxic products including NO. NO 
can easily diffuse through alginate as a soluble gas. NO will kill islets limiting the 
effectiveness of the graft. Figure adapted from Thu, 1996. 
 
2.9 Conclusion 
Fortunately, the innate immune system possesses a variety of cell types and 
cellular products for the protection of the human body from deadly pathogens. 
Unfortunately, this complicates the discovery of preventing immune reactions to 
biomaterials used to encapsulate donor tissue. A defined strategy of using one major 
cell type (macrophages), cytokine (INF-γ), and material impurity (LPS) yields 
significant practical information about acceptable levels of NO in inflammatory 
immune responses to encapsulated cell grafts. This provides a better understanding of 





Chapter 3: Determination Of the “No Observable 
Effect Level” (NOEL) in vitro For Endotoxin Impurity 




The endotoxin LPS is a common contaminant in pharmaceutical grade 
alginate and is also known to cause an inflammatory response. If alginate is to be 
used to encapsulate islet cells for the treatment of type I diabetes, acceptable 
threshold levels of endotoxin need to be determined for providing insignificant 
immune responses that otherwise might be capable of damaging sensitive donor 
islets. It has been determined in pervious studies in this laboratory that islets are 
severely sensitive to NO produced by macrophages, effectively limiting their ability 
to respond to glucose and produce insulin. To help overcome this barrier to the 
development of encapsulation of donor tissue, the NOEL and LOEL of free LPS on 
RAW were determined. Those levels can then be compared to those seen when 
endotoxin contaminates in pharmaceutical alginate. These findings can then be 
applied in regulatory applications. Since macrophages produce significant, sustained 
amounts of NO when in the presence of a pathogen, and NO is readily converted to 
nitrite in media, measurement of nitrite concentration using the 2, 3-
diaminonapthalene (DAN) assay directly correlates with the strength of the 




The T-cell mediator, IFN-γ, is produced in complex immune reactions and 
stimulates macrophages to produce even more NO. To simulate such a reaction, 
RAW264.7 was stimulated with an external dose of IFN-γ in the presence of free 
LPS. The NOEL and LOEL’s of free LPS and LPS contaminated alginate with or 
with out IFN-γ were compared to determine acceptable levels of LPS contamination. 
The NOEL and LOEL was determined for LPS in the absence or presence of IFN-γ to 
simulate simple and complex immune responses and to show the full possible range 
of the inflammatory response. 
3.2 Experimental Design 
3.2.1 Reagents 
Lipopolysaccharide (from Escherichia coli Serotype O26:B6) (LPS), mouse 
recombinant interferon gamma (mIFN-γ), and 2, 3-diaminonapthalene (DAN) were 
purchased from Sigma. LAL reagent water (endotoxin content < 0.005 EU/mL) was 
purchased from Cambrex. Sterile sodium alginate (Pronova SLG 20, viscosity >100 
mPas, guluronate ≥ 60%, endotoxin ≤100 EU/g) was purchased from Nova Matrix 
(Drammen, Norway). Stock solutions were prepared as follows. LPS was diluted in 
dimethyl sulfoxide (DMSO) to a concentrate of 250 μg/mL and frozen at -70oC until 
use. Mouse recombinant interferon gamma was initially diluted to 1 mg/mL in 
phosphate buffered saline pH 8.0, then to 1 μg/mL in complete medium (RPMI 1640 
medium containing 10% FCS, 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL 




mg/mL, were prepared by diluting 100 mg DAN in 5 mL of DMSO, and freezing at -
20oC.   
 
3.2.2 Cell Culture 
The murine macrophage cell line, RAW 264.7 (ATCC TIB71), was obtained 
from the American Type Culture Collection. The macrophage cell line was 
established through the inducement of a tumor in an adult male Mus musculus 
(mouse) with Abelson murine leukemia virus. The method is described in Raschke et 
al. (1978). 
The RAW cells were cultured in CM, expanded in numbers, frozen down in 
10% DMSO-containing CM and stored in liquid nitrogen.  A vial containing up to a 
million cells of RAW 264.7 was taken from the standard stock passage maintained in 
liquid nitrogen, rapidly thawed, and seeded into a T75 flask containing 20 ml CM. 
The flask was cultured until the adhered monolayer of cells had reached 50% 
confluency (usually in one to two days).  The monolayer was washed twice with 
calcium/magnesium-free phosphate buffered saline (Ca/Mg-free PBS), then allowed 
to sit in 10 ml of Ca/Mg-free PBS for five minutes.  The flask was sharply rapped 
several times to dislodge the cells, poured into 10 ml of CM, cell density determined, 





3.2.3 96-well Plate Layout 
The macrophage cell line, RAW was plated out into a 96-well plate as 1x104 
cells/well to a final volume of 0.2 ml (Fig. 5).  After initial seeding, the cells were 
allowed to adhere to the bottom of the wells by further culturing for 24 hours.  
Following the adherence period, 10 μL of LPS standard or 40 μL of packed alginate 
beads spiked with LPS were added to the wells.  The bottom half of the 96-well plate 
received an additional 10 μL dose of IFN-γ, maintaining the same volume in each 
well (Fig. 5). After the desired incubation period, the top 20 μl of supernatant was 
taken from each well to a duplicate plate, which was then stored at -70oC and later 













Figure 5. Layout of 96-well Plate Used for Free LPS Stimulation of RAW264.7 +/- 
IFN-γ.  The volume of each well was maintained at 0.2 mL. Across the top of the 
“96-well plate” is the dose curve of LPS (ng/mL). Each well of the plate contains 10 
μL of the appropriate concentration of LPS. The top half of the plate contains no IFN-





3.2.4 DAN Assay 
A working DAN solution of 50 µg/ml was prepared by making in 0.62 M 
HCL a 1:400 dilution of thawed 20 mg/ml stock solution.  All assays were conducted 
in 96-well plates, with each condition done in quadruplet.  In each well, 20 µL of 
standard (NaNO2), sample, or medium-only was added to 80 µL of d.i. water.  Then, 
10 µL of working DAN solution was added to each well.  The plate was allowed to sit 
in the dark at room temperature for ten minutes.  To stop the reaction, 20 µL of 2.8 M 
NaOH was added to each well in the same timing and sequence as for the additions of 
DAN. Then the plate was gently shaken for one minute in the dark; subsequently it 
was read in a fluorescence plate reader (Perkin Elmer HTS 7000 Plus Bio Assay 
Reader) with an excitation of 360 nm and an emission of 430 nm. Statistical analysis 
was performed using the t-Test assuming unequal variances method in Microsoft 
Excel.  
 
3.2.5 Production of 2 % w/v “Spiked” Alginate Beads 
Alginate was dissolved in LAL Reagent Water and left on the bench top over 
night to give a 2% w/v alginate solution. A dose curve was made by incorporating 
different concentrations of LPS into 2% “Super Pure” alginate (Pronova alginate ≤ 
100 EU/g). The solution was then vortexed to ensure complete mixing. Beads of 
approximately 500-550 μm in diameter were made using a Nisco Engineering 
Encapsulator Unit (Norway) (Fig. 6) with the following settings: voltage 6.5 kV, flow 




The technology behind the encapsulator unit (Fig. 7) relies on creating an 
electrostatic field between the nozzle and the CaCl2 bath (or hardening solution). The 
nozzle is electrically ground and the syringe pump provides steady flow through the 
nozzle causing it to vibrate. This causes the electrostatic field to “pull off” the beads 
from the outer part of the nozzle with uniform size (Fig. 8). However, there are 
deviations in bead size that can be due to mechanical and physical properties. The 
productivity and size distribution relies on nozzle diameter, flow rate, voltage, 
distance between the nozzle and surface of the CaCl2 solution, and any pressure drops 
due to small nozzle diameters. Physical properties that affect size distribution are 
density, viscosity, and surface tension of the gel (Thu 1996). 
  
Figure 6. Nisco Engineering Encapsulator. Used to produce 500 μm in diameter 2 








Figure 7. The Principle of the Encapsulator. Using an exact voltage setting and flow 
rate beads are pulled off the needle at a precisely controlled size. Beads form on the 
outer edges of the needle. Therefore, the given outer diameter of needle gives the 
approximate size of the beads. (Not drawn to scale) 
 
 
Figure 8. 2 % w/v Pronova- 20 Beads Made with Nisco Engineering Encapsulator. 
Settings: 6.5 kV, 0.5 mm diameter needle, 20 mL/hr pump speed, and 1.3 cm arm 
height. Beads are approximately 500 μm in diameter and are uniform in shape and 
size. 
 
 A crosslinking solution was prepared by dissolving CaCl2 in d.i. H2O to a 
concentration of 50 mM. To remove any contaminants that might be present, the 
solution was filtered using a Corning sterilizing, low protein binding membrane (0.22 
μm). The beads were allowed to gel for 30 min in the CaCl2 solution after the last of 




collected, excess 50 mM CaCl2 solution was removed, and the beads were washed 
three times with CM. The beads were incubated at 4oC overnight in CM until use. 
“Packed Beads” were achieved by removing excess CM from the top of settled beads 
immediately before use (Fig.9). Using a clipped sterile pipet tip, 40 μL of beads were 
added to each well on top of RAW and incubated overnight.  
 
Figure 9. Schematic of Sterile “Packed Beads” with Pipet. Beads were incubated in 
a minimum of CM to ensure that a reproducible number of beads could be delivered 
to each well. The pipet was disinfected with a 70% EtOH solution prior to use and the 
end of a pipette tip was removed with a sterile scalpel at an angle.  
 
 
3.3 Experimental Results 
3.3.1 LPS Stimulation of RAW264.7 
The supernatants of each well in the 96 well plate were assayed for nitrite 
concentration using the 2,3-diaminoaphthalene (DAN) fluorescence assay after 
exposures to a standard lot of LPS. The Endotoxin Unit (EU) activity was assayed 
previously in our lab and was found to be 0.6 EU/1.0 ng/mL. Micromolar 
concentrations of nitrite produced by RAW in response to LPS were observed at 20 h. 
The response to differing amounts of LPS followed in a dose dependent manner. This 




The RAW cells experience morphological and proliferative changes in 
response to varying doses of LPS. RAW exposed to no LPS were greater in number 
and increased in number over time (Fig. 10 A-B) and were more rounded in 
appearance covering less individual surface area. When exposed to LPS, RAW cells 
were fewer in number (denoting inhibited proliferation of the cell line), larger, and 
more spread out (denoting differentiation to mature, activated macrophages) over the 
surface of the well plate (Fig. 10 C-D). This trend was seen over increasing doses of 
LPS with even fewer cell numbers and increased cellular surface area up to 6.0 
EU/mL LPS. After 48 h, the well surface of the control (Fig. 10 B) (RAW with no 
LPS) was completely covered in cells with crowding while at the highest dose of LPS 













Figure 10. Comparison of RAW264.7 at 20 and 48 h In the Presence or Absence of 
LPS. A) RAW culture at 20 h in the absence of LPS and IFN-γ, cells are spaced out 
and round in appearance with very little crowding. B) Control RAW at 48 h without 
LPS or IFN-γ, cells completely covers the bottom of the well with significant 
crowding and overlap at the upper left of the picture. C) RAW exposed to LPS at 20 
h. There are fewer cells than in control wells. Morphologically, cells are less round 
and many of the cells have adhered and spread out over the bottom of well in 
irregular shapes. These morphological changes indicate a slow down in proliferation 
with concomitant production of NO. RAW exposed to LPS at 48 h. There is much 
less cellular crowding even though are more cells compared to C. Many of the cells 
have flattened out indicating cell activation and NO production.  
 
The NOEL and LOEL (Fig. 11) were determined at each time point and are 
summarized in Table 1. In general, the NOEL and LOEL for each time point is 
similar over the time course. Significance of LOEL was determined using the two-
tailed Student’s t test assuming unequal variances. The first significant difference 




taken as the LOEL with the NOEL being the previous concentration of LPS. For the 
20 h time point, the LOEL was 0.03 EU/mL LPS which was the first concentration 
that elicited a significant increase in nitrite concentration compared to the control; 
therefore, the NOEL was 0.018 EU/mL of LPS. At 24 h, the NOEL and LOEL 
decreased to 0.006 EU/mL LPS and 0.018 EU/mL LPS respectively. While at 48 h, 
the NOEL and LOEL increased back to the original NOEL and LOEL. Overall, the 
NOEL was detected down to a level of 0.006 EU/mL LPS and the LOEL was 




















































* ** * ** * **
 
Figure 11. LPS Stimulation of RAW264.7 NO Production. LPS causes NO 
production in a dose dependent manner whose trend is amplified over time. Samples 
were taken over three time points: 20, 24, 48 hrs. The NOEL(*) and LOEL(**) values 
are indicated at each time point. The NOEL was detected down to the level of 0.006 






Time  LPS 
(EU/mL)
NO2 (μM) P-value 
P(T≤t)=0.05 
Variance 
20 h NOEL 0.018 0.40 0.06 0.27 
 LOEL 0.03 1.2 7 x 10-3 0.056 
      
24 h NOEL  0.006 2.3 0.2 0.66 
 LOEL 0.018 2.8 6 x 10-4 0.031 
      
48 h NOEL 0.018 0.80 0.4 0.79 
 LOEL 0.03 1.2 0.04 0.029 
Table 1. Summary of NOEL and LOEL Values for LPS Stimulation of RAW264.7 
at 20, 24, 48 h. Significant NOEL and LOEL values were determined using the 
Student t-test and were presented with their corresponding NO2 concentrations, P-
values, and variance. Cut off for significance was P(T≤t) = 0.05. 
3.3.2 Determination of NOEL and LOEL for LPS 
Contamination in 2 % w/v Alginate in the Absence of IFN-γ 
A nitrite response was observed over the entire time course in a dose 
dependent manner compared to the control (Fig. 12). Even the 2 % w/v sterile 
alginate beads containing no added LPS elicited a significant nitrite response at 20 h. 
The sterile Pronova alginate contains less than 100 EU/g of endotoxin. This 
demonstrates the sensitivity of the assay, the reactivity (albeit very small) of even 
highly-purified alginate, and the applicability of using RAW264.7 as a way to predict 
acceptable levels of endotoxin contamination. Overall, the “spiked” alginate elicited a 
much lower nitrite response compared to its free LPS counterparts indicating that 
much higher amount of contamination can be present in alginate than free LPS.  
Over the course of the experiment, the NOEL and LOEL increased. However, 
the NOEL’s and LOEL’s were much lower than expected so further investigation 
using a lower range of LPS contamination was conducted to determine if there were 




EU/mL “spiked” alginate beads produced a moderate NO response at each time point, 
2 EU/mL “spiked” beads were used as the highest concentration so as to not miss any 
potential NOEL and LOEL values. Lower doses of “spiked” alginate beads were 
freshly made as described previously. Again, there was a significant nitrite response 
at all time points and at each dose of “spiked” beads. However, at 20 h and 24 h the 
LOEL was again 0 EU/mL. While at 48 h, the NOEL was 0.5 EU/mL LPS and the 









































Figure 12. Stimulation of NO Production of RAW264.7 by LPS “Spiked” 2 % w/v 
Alginate Beads. A dose curve of nitrite concentration due to LPS “contamination” in 
alginate seen over each time point (20, 24, and 48 h).  NOEL (*) and LOEL (**) 
values are indicated at each time point. Even the beads with no added exogenous LPS 


















20 h NOEL None    
 LOEL 0 1.6 0.01 3.4 x 10-4
      
24 h NOEL  0 1.5 0.3 0.085 
 LOEL 1 1.7 0.05 0.078 
      
48 h NOEL 2 5.6 0.09 34 
 LOEL 3 7.7 0.03 20 
 
Table 2. Summary of NOEL and LOEL Values for “Spiked” Alginate Beads 
Stimulation of RAW264.7 at 20, 24, 48 h. The NOEL and LOEL values were 
determined using the Student t-test and were presented with their corresponding P 
values and variance. Cut off for significance was P(T≤t)=0.05. The NOEL and LOEL 


















































** ** * **
 
Figure 13. Narrower Range of LPS “Spiked” 2% w/v Alginate Beads for 
Stimulation of RAW264.7 Production of NO. NOEL(*) and LOEL(**) are indicated 
at each time point. There is a dose dependence of LPS contamination and NO2 














20 h NOEL None    
 LOEL 0 1.8 0.02 0.042 
      
24 h NOEL  None    
 LOEL 0 3.7 2 x 10-3 0.083 
      
48 h NOEL 0.5 3.3 0.07 0.97 
 LOEL 0.75 5.7 0.02 1.2 
Table 3.  Lower NOEL and LOEL Values for “Spiked” Alginate Beads Stimulation 
of RAW264.7 at 20, 24, 48 h. The NOEL and LOEL values were determined using 















20 0.6 0.821 3 0.894 
24 0.6 3.05 3 2.62 
48 0.6 1.18 3 7.67 
     
20 6 6.35 30 4.44 
24 6 13.5 30 8.78 
48 6 54.4 30 42.6 
 
Table 4. Comparison of Free LPS Versus Incorporated LPS Into Alginate NO2 
Concentrations. Overall, an amount five times the amount of free LPS can be 
incorporated into alginate to give similar a NO response by RAW264.7. 
 
3.3.3 LPS Stimulation of RAW264.7 in the Presence of IFN-γ 
To simulate a more complex immune reaction a T-cell mediator, IFN-γ, was 
used to further stimulate NO production by RAW. The same procedure was followed 
as above except that before the incubation period began an additional 10 μL of IFN-γ 
was added to the media along with a standard lot of LPS. The assay used to quantify 
the nitrite concentration was the same. As stated before, IFN-γ is produced by 




alert nearby cells to a pathogen and causes the amplification of cellular activity in 
immune cells, especially macrophages such as RAW264.7. Other studies have 
established the synergistic effect of IFN-γ and LPS on NO production (Lowenstein et 

















































Medium Only + mrIFN-γ
RAW264.7 Only + mrIFN-γ




Figure 14. LPS Stimulation of RAW264.7 In the Presence of IFN-γ. The LOEL was 
determined to be 0.006 EU/mL for both 20 h and 24 h therefore the NOEL is less than 
0.006 EU/mL. No NOEL and LOEL were reported for 48 h due to the large 
fluctuations in nitrite concentration.  NOEL(*)  and LOEL (**) values are indicated at 
each time point. There is an increase in nitrite concentration for each dose compared 
























20 h NOEL ≤ 0.006    
 LOEL 0.006 2.5 0.02 9.0 x 10-3
      
24 h NOEL  ≤ 0.006    
 LOEL 0.006 7.4 0.03 0.27 
      
48 h NOEL N/A  N/A N/A 
 LOEL N/A  N/A N/A 
 
Table 5. Summary of NOEL and LOEL Values for LPS and IFN-γ Stimulation of 
RAW264.7. The significance of NOEL and LOEL values were determined using the 
Student t-test and were presented with their corresponding NO2, P-values, and 
variance. 
 
 A strong nitrite response was seen over the range of LPS doses for 20 and 24 
h (Fig. 14). The NO2 concentrations for each LPS dose were dramatically higher than 
the previous corresponding graph (Fig. 11) where no IFN-γ was present. Also, there is 
still a correlation at these time points between NO2 and LPS concentration. However, 
at 48 h no more correlation exists between LPS and NO2.  At 48 h, the nitrite 
concentrations seem to fluctuate or “max out” compared the control. Given the 
documented synergistic effect of IFN-γ on nitrite concentration, there were no 
detectable NOEL levels when compared to the control. The IFN-γ served as a tool to 
amplify the NO response by RAW giving much lower LOEL’s compared to the 
absence of IFN-γ. The LOEL for 20 and 24 h was both 0.006 EU/mL LPS. 
 The control contained no LPS but 50ng/mL of IFN-γ (Fig. 15 A). The cellular 
morphologies and numbers were different then in the absence of IFN-γ (Fig. 10 A). 
The presence of a cytokine in solution causes the RAW cells to stop proliferating as 




different from that of the control containing no LPS or IFN-γ. The cellular 
morphology was more spread out and fewer in number corresponding to a greater 
nitrite concentration than the previous control. With the presence of IFN-γ, the 
appearance of RAW cells were more spread out at even lower doses of LPS compared 




Figure 15. Comparison of RAW 264.7 at 20 and 48 h In the Presence of LPS and 
IFN-γ. A) Control at 20 h in the presence of IFN-γ. RAW cells are fewer in number 
than the previous corresponding medium only control and flatter in appearance. B) 
Cells at 48 h in the presence of only IFN-γ. RAW cells look dramatically different 
than from those in the medium only wells. There are fewer cells and a granular 
appearance to the cells indicating cellular death. C) RAW cells in the presence of LPS 
and IFN-γ. RAW cells are fewer in number, flatter, and more spread out. D) RAW 
cells in the presence of LPS and IFN-γ at 48 h. Much fewer cells are present and 




3.3.4 Determination of NOEL and LOEL for LPS 
Contamination in 2 % w/v Alginate In The Presence of IFN-γ 
 In the presence of IFN-γ, similar trends of proliferation and morphology were 
seen for “spiked” alginate beads as in the free LPS case. A dose dependent nitrite 
response to entrapped LPS was observed in the presence of IFN-γ (Fig. 16). The 
response was amplified, however compared to the case when no IFN-γ was present, 
with much higher NO2 concentration. The LOEL was determined to be 1 EU/mL for 
both the 20 h and 24 h, with the NOEL being 0 EU/mL (Table 6).  
Considering the fact that the NOEL and LOEL were so low, a narrower range 
(0-2 EU/mL) of exogenous LPS contamination was examined in the presence of IFN-
γ (Fig. 17). At 20 h, the LOEL was determine to be 0.25 EU/mL LPS and the NOEL 
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Figure 16 “Spiked” 2 % w/v Alginate Beads Stimulation of RAW264.7 In the 
Presence of IFN-γ. For 20 h and 24 h, a dose dependent nitrite curve is observed. At 
48 h, RAW has “maxed-out” resulting in large fluctuations in nitrite concentration. 
The NOEL is indicated by (*) over the LPS dose and the LOEL (**). 
 
 







20 h NOEL 0 3.5 0.2 0.86 
 LOEL 1 7.1 7 x 10-4 0.11 
      
24 h NOEL  0 5.6 0.2 3.8 
 LOEL 1 12.7 3 x 10-3 1.4 
      
48 h NOEL N/A    
 LOEL N/A    
Table 6. “Spiked” 2 % w/v Alginate Beads NOEL and LOEL Values In the 



















































20 hrs 24 hrs 48 hrs
"Spiked" Beads + mrIFN-γ
Medium + mrIFN-γ Only
RAW264.7 + mrIFN-γ Only
* **
**
Figure 17. Stimulation of NO Production of RAW264.7 by LPS “Spiked” 2 % w/v 
Alginate Beads Over a Narrower Concentration of LPS In the Presence of IFN-γ.  
Lower values for the LOEL and NOEL were determined at 20 h and 24 h were 
determined. The LOEL was determined down to 0 EU/mL “spiked” beads. The 
NOEL(*) and LOEL (**) values are indicated at each time point with the exception 
of 48 h. 
 
 







20 h NOEL 0.1 5.2 0.3 0.21 
 LOEL 0.25 6.1 7 x 10-3 0.28 
 24 h     
24 h NOEL  None    
 LOEL 0 9.7 4 x 10-3 0.48 
 48 h     
48 h NOEL N/A    
 LOEL N/A    
 
Table 7. Summary of NOEL and LOEL Values for LPS “Spiked” 2 % w/v Alginate 
Bead In the Presence of IFN-γ. Even lower LOEL and NOEL values were 




















20 0.6 6.98 3 9.35 
24 0.6 15.1 3 15.6 
48 0.6 N/A 3 N/A 
     
20 6 14.7 30 14.1 
24 6 20.5 30 20.8 
48 6 N/A 30 N/A 
Table 8. Comparison of Free LPS Versus Incorporated LPS In Alginate In the 
Presence of IFN-γ. Five times the amount of LPS incorporated in alginate needs to 




The free LPS stimulation of RAW in the presence or absence of IFN-γ 
demonstrates the usefulness and sensitivity of using the DAN assay to quantify nitrite 
concentrations as a way to study NO production by RAW. The assay helps define the 
ability of the biomaterial alginate to sequester LPS. Two cases were studied: LPS 
stimulation and LPS stimulation with IFN-γ.  For the case of the LPS dose curve in 
the absence of IFN-γ an overall increasing trend was observed, NOEL’s and LOEL’s 
were established, and the NOEL and LOEL levels were similar for each time point 
(Table 1).  
 When comparing the two sets of data together, there is a significant increase 
in nitrite concentration in the case of LPS + IFN-γ compared to LPS alone (Table 5). 




macrophage cell line was used in further studies as a way of quantifying 
contamination found in alginate. Using IFN-γ gives the assay a much greater 
sensitivity towards LPS concentration and demonstrates that LPS contamination of 
biomaterials needs to be viewed in both the simple and more complex immune states 
that individual recipients may exhibit. Even lower NOEL’s and LOEL’s can be 
established for alginate contamination in the presence of IFN-γ versus its absence. At 
the 48 h time point with LPS + INF-γ there was no more obvious trend in nitrite 
response (Figs. 16 & 17). This could be attributed to the death of RAW cells caused 
by high levels of metabolic activity. 
 Observationally, with time the media solution becomes increasingly more 
yellow due to an increase in acidity in the solution. By the 48 h time point, the media 
solution is yellow, indicating a highly acidic environment which is potentially 
unfavorable for cellular survival. The RAW cells eventually die, ceasing to produce 
more NO. 
The seeming fluctuations in the NOEL and LOEL values between 
experiments and time points are not unexpected.  The DAN assay gives benchmark 
values for the NOEL and LOEL to be used along with other similar cytokine assays 
in determining acceptable levels of contamination. The NOEL and LOEL values are 
expected to slightly fluctuate from experiment to experiment reflecting biological 
variability in the most carefully replicated experimental conditions. As demonstrated 
earlier, it is possible for the DAN assay to detect differences for very small LPS 




RAW response. Therefore, due to the biological variability it serves only as a tool for 
approximating a significant range for NOEL and LOEL values. 
Exogenous LPS incorporated in 2 % w/v alginate beads made from 
pharmaceutical grade alginate produced similar trends for nitrite concentrations, as 
observed with free LPS +/- IFN-γ. However, a much higher concentration of LPS, at 
least five times more in both cases without or with IFN-γ (Tables 3 & 8), had to be 
incorporated into the alginate to give equivalent nitrite concentrations compared to 
free LPS. Given the structure of alginate mesh structure formed in the presence of 
Ca+2, LPS could be trapped inside the gel and effectively removed from detection by 
RAW.  Another possibility could be that one the main factors that contributes to 
RAW cells producing NO in response to LPS is a surface area exposure effect. As 
spheres, alginate has less surface area contact with RAW cells. LPS incorporated into 
alginate causes RAW to produce much less NO production than free LPS. Therefore, 
alginate seems to sequester LPS causing the RAW cells to be actually exposed to less 
direct LPS. Regardless of the mechanism, these results suggest the inflammatory 
potential of LPS within a biomaterial is less that that predicted on the basis of free 





Chapter 4: Determining the Effects of Endotoxin and 




Given the small surface area of each well in the 96-well plate, having a 
uniform layer of alginate completely cover the bottom of the plate was impossible to 
achieve in our lab due to the rapid gelation effect of CaCl2 solution. The alginate gel 
would end up all on one wall of the well or the surface would be highly congurated 
no matter the care in adding the CaCl2 solution. Also, there was concern about the 
ability of the RAW cells adhering to the alginate surface, functioning properly, and 
proliferating. This led to using the encapsulator to make beads out of the alginate and 
putting the beads on top of the RAW cells that had already adhered to well surface.  
 Given increased NO production in response to LPS added to alginate, the 
effect of varying the macrophage contact with the alginate was important to 
investigate. There has been some debate in the literature about the benefits of small 
versus large beads in regards to diffusion of nutrients, waste, and soluble gases (De 
Vos et al. 2002).  The effect of large versus smaller beads in regards to inflammation 




To study the effect on inflammation, a variety of different total alginate 
volumes per well and different sizes of 5 EU/mL beads were used. A moderate 
amount of LPS (5 EU/mL) was chosen to test this effect so the assay would not be 
overpowered by a stronger dose and any subtle effects could be teased out. Only the 
20 and 24 h time points were examined since at 48 h, especially in the presence of 
IFN-γ, the NO2 concentrations become so high that dose curve responses would no 
longer be readily detectable. 
4.2 Experimental Design 
All reagents, cell culture methods, and assays were prepared in the same 
manner as described above with the inclusion of forming the different sized beads. 
Aliquots of packed beads were added to the 96-well plate in a similar manner as 
described in Chapter 3.  
 
4.2.1 Production of Different Size Beads 
Below is Table 9, gives the settings used on the encapsulator to achieve the 
appropriate bead diameters.  All batches of beads were allowed to incubate for 30 
mins. in CaCl2 to ensure complete gelation. The beads were washed three times with 



















0.20 7.5 5.5 200 
0.35 7.5 6.0 350-400 
0.50 15 6.5 500 
0.70 15 6.5 750 
1.1 7.5 6.5 ~1000 
Table 9. Encapsulator Settings for the Production of Different Sized Beads. Bead 
sizes were confirmed with an inverted phase microscope using a calibrated eye piece.  
 
4.3 Experimental Results Beads of a Different Size 
4.3.1 Beads of a Different Size 
Beads of different sizes were made by varying the voltage and the needle 
diameter. To study surface contact effects, it was thought that beads of small diameter 
would have more contact with the RAW cells which might exacerbate a NO response; 
while beads of a larger diameter would have less contact with the RAW cells (Fig. 
18). In the previous study 40 μL aliquots of beads were used to ensure that the entire 
well was covered with alginate beads. In fact sometimes there would be multiple 
layers of beads. Therefore to negate any effect due to the pressure of beads pushing 
down on other beads a 10 μL aliquot of beads varying in diameter was first used to 
obtain a monolayer of beads over the bottom of the plate.  
A study, shown below, consisted of using a range of differing delivery 
volumes (5-40 μL) for 500 μm diameter beads to determine if there was a difference 
in delivery volume of NO2 concentration. The purpose was to determine the lowest 




information was used to determine what volume would deliver a monolayer of beads 
to the bottom of a well. 
VS.
 
Figure 18. Schematic of Ideal Wells Containing Beads of Varying Diameters In 
Contact with RAW264.7 Adhered To the Bottom of the Plate. Beads of smaller 
diameter would have more direct contact with the bottom of the well while larger 
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Figure 19. Different Delivery Volume for Beads of 500 μm In Diameter In the 
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Figure 20. Effect of  Delivery Volumes for  Beads of 500 μm In Diameter On NO 
Production In the Presence of IFN-γ. 
 
In the absence of IFN-γ, there seemed to be conflicting evidence whether 
increasing the volume causes an increase in NO2 concentration (Fig. 19).  At 48 h, 
there was some evidence that a dose curve based on delivery volume might be 
present. More evidence seemed to support this theory when IFN-γ was present at 20 
and 24 h (Fig. 20). One possibility for this weak correlation was that the NO2 
concentrations are so low that the DAN assay cannot easily detect such minute 
differences in concentration. The beads contain 5 EU/mL of LPS (a moderate dose), 
however given that different volumes of beads are delivered to the well there are, 
theoretically, different amounts of LPS present due to the varying number of beads. 
Also, there were multiple layers of beads at the higher volumes. Given that 10 μL was 
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Figure 21.  Using 10 μL Aliquots To Deliver Beads of Varying Diameter 
Containing 5 EU/mL of Exogenous LPS. A NO2 dose response is seen at 20 h. The 
NOEL (*) occurs at beads of 400 μm and the LOEL is at beads of 200 μm. No 
obvious trend was seen at 24 h since none of the conditions were significantly 
different from the control RAW. 
 
 





P (t≤T) = 
0.05 
20 h NOEL 400 1.644 0.3 
 LOEL 200 2.073 0.05 
     
24 h NOEL  N/A   
 LOEL N/A   
Table 10.  Summary of NOEL and LOEL Values of Bead Stimulation of RAW264.7 










































 Bead Diameter + mrIFN-γ
Medium Only + mrIFN-γ
RAW264.7 Only + mrIFN-γ
20 hrs 24 hrs
 
Figure 22. Graphical Results of 10 μL Aliquots of Bead Diameters Ranging From 
~200-1000 μm In Diameter Containing 5 EU/mL LPS In the Presence of IFN-γ. 
No obvious NO2 trend or NOEL/LOEL values could be determined due to the 
increased sensitivity of RAW by IFN-γ.  
 
 All bead preparations contained a concentration of 5 EU/mL LPS to ensure a 
reasonable NO response that was measured by the DAN Assay. Bead diameters were 
varied from approximately 200 to 1000 μm. The increments and sizes were 
determined by varying the needle diameters. Bead diameters were confirmed using an 
inverted phase microscope. All measurements were done in quadruplet. In the 
absence of IFN-γ, a NO response was observed compared to the control (Fig. 21). The 
amount of NO2 present decreased with increasing bead size. Upon inspection, the 
wells that had smaller bead diameters contained many more beads. In fact, for the 200 
and 400 μm case, a simple monolayer was not achieved; instead there was overlap of 




monolayer of beads 750 or 1000 μm in diameter actually only had a few beads; 
insufficient for a monolayer (Fig. 23). 
VS.
 
Figure 23. Schematic of Two Different Wells Containing Beads of Much Different 
Diameter. Beads of a smaller diameter formed multiple layers at the bottom of the 
well while beads of a larger diameter contained not enough beads to cover the bottom 
of the well. (Not drawn to scale) 
 
 In the presence of IFN-γ, the NO2 concentration increased for every condition 
(Fig. 22). All of the bead diameters at both time points contained significantly more 
NO2 compared to the control of RAW with no beads. However, the relationship 
between inverse bead diameters to NO2 concentration was absent. Therefore, it was 
decided that different aliquots would be used for each bead diameter.  
4.3.2 Beads of Varying Diameter and Delivery Volume 
Since using a 10 μL aliquot of alginate beads did not ensure only a monolayer 
beads at the bottom of the well, the experiment was repeated with some 
modifications. Through trial and error different delivery volumes were determined for 
each bead diameter. For the case when 10 μL of 200 μm beads gave multiple layers 
of beads at the bottom of the well, the delivery volume was not changed due to 
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Figure 24. Modified Dose Curve with Bead Diameter and Delivery Volume In 
Parentheses In the Absence of IFN-γ. The NOEL(*) was for beads of 500 μm in 
diameter and the LOEL (**) was 400 μm for 20 h. For the 24 h time point, the NOEL 
(*) was 400 μm and the LOEL (**) was 200 μm. An inverse NO2 response was seen 
in relation to the bead diameter. 
 










20 h NOEL 500 17.5 0.4976 0.06 
 LOEL 400 20 0.7448 0.006 
      
24 h NOEL  400 10 0.4875 0.06 
 LOEL 200 10 0.7161 0.04 
 
Table 11. Tabular Results of Modified Dose Curve Experiment with NOEL and 
LOEL’s Listed for Each Time Point. 
 
 Again, there was an inverse relationship between bead diameter and NO2 
concentration in the absence of IFN−γ (Fig. 24). Beads of 200 μm caused the highest 
increase in NO2 compared to the control (RAW cells with no beads present) due to 




experiment are not as dramatic as in the previous study, the inverse relationship 
between bead diameter and NO2 concentration lends support to the use of larger 
beads for encapsulation of islets. The larger beads might provide better protection 
from macrophages due to less actual contact per contained unit of islet cells. In the 
case when IFN-γ is present, similar results were obtained as before in the 10 μL case 
with no obvious dose trend except that there was a significant increase in NO2 at each 







































 Bead Diameter + mrIFN-γ
Medium + mrIFN-γ
RAW264.7 + mrIFN-γ
20 hrs 24 hrs
 
Figure 25. Modified Bead Delivery Experiment with Varying Delivery Volumes In 
the Presence of IFN-γ. An increase in NO production is seen at each condition which 













4.4.1 Conclusions of Beads of a different size 
The hypothesis for this set of experiments that increased direct contact 
between the beads and the RAW cells would cause an increase in NO production. The 
logic behind this was that smaller beads have a smaller surface area therefore many 
more beads would have a point of contact to the RAW cells (Fig. 18). This increase in 
contact with the RAW cells would increase NO production due, to the greater extent, 
of the documented phenomenon of macrophages becoming more active when they 
sense that they can not engulf foreign bodies and instead increase production of toxic 
immune mediators. Larger beads would have less actual contact with fewer RAW 
cells, decreasing RAW activation. 
In the absence of IFN-γ, a dose response to beads of differing diameters was 
present (Table 10). The inverse relationship between bead diameter and NO2 
concentration was likely due to the wells with smaller sized beads contacting RAW 
cells more that the same volume large beads. The increased response to the LPS in 
alginate with beads of a smaller diameter was not evident in the presence of IFN-γ. 
This demonstrates the potency of IFN-γ to sensitize the RAW cells to produce 
maximal NO levels even in the presence of a minute amount of endotoxin. This 
would model a “HOT” immune response where macrophages have already been 
activated by a cytokine and produce a sustained level of NO. A minor variation on 
degree of direct contact between the encapsulated beads and the tissue macrophages 





4.4.2 Conclusions to Varying the Diameter and Volume of 
Beads 
By maintaining a monolayer of beads between wells and while varying bead 
size, surface contact effects between beads and RAW could be studied. The observed 
inverse response to bead diameter and NO2 concentration supports the idea that 
having smaller beads does result in more contact with the RAW cells, evoking a 
greater response (Table 11). An increase in the bead size, conversely, decreased the 
contact between the beads and the RAW cells, therefore causing a decrease in 
inflammatory response to endogenous LPS contaminated alginate. From the previous 
experiments it was seen that since much more LPS can be incorporated into the 
alginate compared to free LPS it must be sequestered by the alginate. However, in 
addition to direct contact effects, minute quantities of LPS may be leaching out over 
time adding to the degree of response. 
 With the addition of IFN-γ, there is a disappearance of any correlation 
between beads size and NO2 concentration (Fig. 25). Increased macrophage 
sensitivity may cause a maximal response due to passing threshold levels of direct 
contact with the LPS-containing alginate or leached LPS. This information is 
important to graft implantation in that when the graft is first implanted there is an 
expected increase in inflammation solely due to tissue trauma at the site. Any IFN-γ 
being elaborated at the site could overwhelm mechanistic effects (such as varying 




Chapter 5:  Comparison of Anti-Inflammatory 





Even small amounts of LPS contamination in alginate can cause a robust NO 
response from RAW. In this series of experiments, different anti-phagocytic drugs 
were incorporated into alginate capsules as a way to retard macrophage attack; 
specifically, NO production. The concept is that macrophages could be inhibited from 
reacting to the impurities in alginate, through drugs leaching out of the gel or through 
direct contact with drug-loaded alginate leading to macrophage death. The ideal drug 
candidate would have to be potent at low (nanomolar to low micromolar) 
concentration and have little to no effect on islet function.  If shown to inhibit 
macrophage activation, such drugs might potentially increase the lifespan of 
implanted alginate encapsulated islets.  
Two classes of drugs, bisphosphonates and parthenolide, were studied for 
their effectiveness on cessation of NO production by RAW; either free in the culture 
medium or incorporated into alginate beads. Both of these drugs have been previously 
studied with respect to macrophages or cell types similar in function to macrophages 




studied demonstrated strikingly different efficiencies for modulating NO production 
by RAW.  
 
5.2 Bisphosphonates: Clondronate and Alendronate 
 
5.2.1 Description of Bisphosphonates 
Bisphosphonates were first used in the 1930’s as a water-softener (Graham et 
al. 2007). Clinically, they are the drugs of choice when treating bone diseases 
involving hypercalcemia and bone resorption. Osteoporosis (brittle bones) is the 
result of overactive osteoclasts, the cellular type responsible for bone breakdown, 
which are derived from the macrophage lineage. Currently, bisphosphonates, though 
most commonly associated with the treatment of osteoporosis, are also used in 
treating Paget disease, myeloma, bone metastases, and pediatric bone diseases. 
Bisphosphonates are suspected to effect osteoclast recruitment, differentiation, 
resorptive activity, and may cause the cells to apoptose. 
Bisphosphonates are analogs of inorganic pyrophosphate, which is a 
byproduct of hydrolyzed adenosine triphosphate (ATP), and is resistant to enzymatic 
breakdown. There are two main types of bisphosphonates (Fig 26): non-amino-
bisphosphonates and amino-bisphosphonates which have different cellular 
mechanisms. Non-amino bisphosphonates, like clondronate (Fig. 27), may inhibit 
ATP-dependent cellular mechanisms possibly through the metabolite β,γ-




bisphosphonates, such as alendronate (Fig. 27), inhibit enzymes of the cholesterol 
synthesis pathway, leading to apoptosis. The exact mechanism of action for either 
class of bisphosphonates is not fully understood but different bisphosphonates are 
more effective than others due to differences in R2 groups.  However, all 












Figure 26. Basic Structure of Bisphosphonate. 
 











Figure 27. Chemical Structures of Clondronate (right) and Alendronate (left).    
 
 Osteoclasts and macrophages both originate from the monocyte/phagocyte 
system and have endocytic properties. Bisphosphonates are preferentially absorbed by 
osteoclasts over other cell types, adding to its success as an anti-resorptive drug. Due 




branched out to demonstrate the potential of bisphosphonates for treating 
inflammatory diseases such as rheumatoid arthritis.  
New research has explored the opportunity of using bisphosphonates, 
specifically clondronate, to deplete peritoneal macrophages as a way to increase the 
survival of encapsulated porcine neonatal islets (Omer et al. 2003). Over time, 
fibroblast overgrowth and macrophages surround and adhere to alginate capsules 
instigating premature failure of islet grafts. A clondronate solution, flushed through 
the peritoneal cavity before graft transplantation, prevented the overgrowth of 
macrophages on the macrocapsules.  
Macrophages become more susceptible to bisphosphonates when they are 
encapsulated in negatively charged liposomes. The Trojan Horse “liposome-mediated 
macrophage ‘suicide’ technique” was described by Van Rooijen et al (1989) as a way 
to deliver bisphosphonates to macrophages to prevent premature bisphosphonate 
hydrolysis in solution, dramatically increasing their potency. Once endocytosied by 
the macrophage, the liposome layer is degraded exposing the bisphosphonate.  
In our present study, two types of bisphosphonates, clondronate and 
alendronate, were used to investigate a decrease in the NO production of RAW under 
a variety of conditions. Clondronate is a non-amino-containing bisphosphonate that 
inhibits DNA activation by NF-κB and AP-2, diminishing cytokines, NO release, and 
iNOS expression; a potentially ideal drug for an anti-inflammation study. 
Alendronate, on the other hand, is an amino-containing bisphosphonate that should 





5.2.2 Experimental Design of Alendronate and Clondronate 
Plates 
The bisphosphonates were dissolved in CM and a dilution curve was made as 
indicated on the plate was prepared as indicated in Figure 28. RAW cells were 
cultured as described previously. All other reagents were made as described 
previously. Each plate contained a combination of LPS, drug, and IFN-γ, Samples 
were taken at 20, 24, and 44 h and analyzed using the DAN assay as described 
previously.  












5.2.3 Results of Alendronate 
Alendronate was tested for the mitigation of NO production by macrophages. 
To simulate an inflammatory situation, low to moderate amounts of LPS (0-6 
EU/mL) were added to the macrophages. Superimposed on the inflammatory stimuli 
was a dose curve (0-175 μM) of alendronate. Measurements were taken at three time 
points: 20, 24, 44 h. Each graph represents one time point in the absence or presence 
of IFN-γ. 
 As shown in previous experiments, increasing the amount of LPS present in 
the culture medium caused an increase in NO2 concentration. However, at moderate 
amounts of LPS (3 or 6 EU LPS) there was no significant decrease in NO2 
concentration at 175 μM compared to 0 μM alendronate at 20 h (Fig. 29). In the 
presence of 0.6 EU/mL LPS there was an inverse dose response to alendronate at all 
the time points. RAW, in an unstimulated state, produced very little NO and was 
unreactive. With a low dose of LPS that is just enough to provide minimal 
stimulation, the RAW cells seemed more inclined to uptake alendronate.   
 At very low amounts of LPS stimulation, especially at 0.6 EU/mL LPS, there 
was an inverse dose response to alendronate. In the case were no LPS was present, 
there was a small inflammatory effect of alendronate seen by increased NO2 levels. 
However, this trend did not progress over time (Figs. 29-31).  
With a very low concentrations of LPS (0.6 EU/mL) there was a clear 
reduction in NO2 with increasing alendronate. Over the course of the experiment, 




compared to 0 μM alendronate. Still, the NO2 concentration at 175 μM in the 
presence of 0.6 EU/mL LPS was significantly higher than the control when no LPS or 
alendronate is present. 
At moderate doses of LPS, 3 or 6 EU/mL, the RAW cells were unreactive to 
alendronate. The stronger LPS effect seemed to overtake any inhibitory effect of 





















Figure 29: Alendronate and LPS Doses Curves at 20 hr. As LPS concentrations 
increase there is an increase in NO2 at all alendronate concentrations. At 3 and 6 
EU/mL LPS there is no significant difference between the control and the highest 
concentration of alendronate (175 μM). Under very mild stimulation of LPS (0.6 

























Figure 30. Alendronate and LPS Dose Curves at 24 h. As time and LPS 





















Figure 31. Alendronate and LPS Dose Curves at 44 h.  The same trends continue 





 The addition of IFN-γ to LPS plus alendronate simulated a more complex 
immune reaction (Figs. 32-34). The addition of INF-γ caused a significant increase in 
NO production compared to the case where IFN-γ was absent. However, the LPS 
controls where no alendronate was present were questionable and the NO response 
was not as strong as expected. Adding alendronate seemed to cause no to very little 
effect on NO2 concentration; neither stimulatory nor inhibitory. Overall, as time 
increased the NO2 levels also increased to the 44 h mark were the RAW cells are 
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Figure 32. Alendronate and LPS Dose Curves In the Presence of IFN-γ at 20 hr. 
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Figure 33. Alendronate and LPS Dose Curves In the Presence of IFN-γ at 24 h. 
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Figure 34. Alendronate and LPS Dose Curves In the Presence of IFN-γ at 44 hr. 




Cytokines, such as IFN-γ, cause macrophages to produce more NO. In the 
previous set of experiments, there were two competing factors on NO production: 
alendronate and LPS. Adding IFN-γ caused less of a decrease in NO2 in the presence 
of alendronate. As the reaction proceeds, the degree of decrease in NO2 diminishes to 
the point where there is no more significant decrease at moderate amounts of LPS. At 
44 h, there was no observable trend due to alendronate being present (Fig. 34). 
5.2.4 Results of Clondronate 
 In the literature, clondronate has been seen in different in vivo systems to 
dramatically decrease the number of macrophages present. In this study, clondronate 
was tested over a range of concentrations, in the presence of various LPS 
concentrations, and the absence or presence of IFN-γ. Contrary to some published in 
vivo results, clondronate seemed to have little effect on NO production. Increasing 
LPS caused an increase in NO2, but the inhibitor effects of clondronate are even less 
evident than was the case with alendronate. Only at 44 h (Fig.37), was a small 
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Figure 35. Clondronate and LPS Dilution Curve at 20 h. Overall there is no 
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Figure 36. Clondronate and LPS at 24 h. No significant decrease in NO2 due to 





















0 EU/mL LPS 0.06 EU/mL LPS 0.6 EU/mL LPS 3 EU/mL LPS 6 EU/mL LPS
 
Figure 37. Clondronate and LPS Dose Curves at 44 h. Addition of LPS results in 
sporadic dose dependencies.  
 
The addition of IFN-γ did not cause the clondronate to be inhibitory (Figs. 38-
40). With the presence of IFN-γ, there was the expected increase in NO2, however in 
this experiment the LPS controls (where no clondronate was present) did not respond 
as robustly as expected. Clondronate either has no effect on the interferon-mediated 
NO increase or only gave a sporadic, small decrease with no consistent (as was 
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Figure 38. Clondronate and LPS In the Presence of IFN-γ at 20 h. No significant 
















Alendronate + LPS + mrIFN-γ
RAW264.7 +mr IFN-γ
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Figure 39. Clondronate and LPS In the Presence of IFN-γ at 24 h. There is an 




















Alendronate + LPS + mrIFN-γ
RAW264.7 +mr IFN-γ
0 EU/mL LPS 0.06 EU/mL LPS 0.6 EU/mL LPS 3 EU/mL LPS 6 EU/mL LPS
 
Figure 40. Clondronate and LPS In the Presence of IFN-γ at 44 h. There is no 
discernable dose dependence. Assay has “maxed” out. 
 
5.3 Parthenolide 
5.3.1 Description of Parthenolide 
Parthenolide is a component of the herb, Feverfew (Tanacetum parthenium) 
(Fig. 41), which has been used for centuries in herbal medicine for the treatment of 
headaches, prevention of blood clots, and in treatment of arthritis (an inflammatory 
disease) (Heptinstal 1988). Sesquiterpene lactones, such as parthenolide, are known 
to be potent inhibitors of the NF-κB pathway (Hehner et al. 1999; Kang et al. 2001; 
Sheehan et al. 2002), the main intracellular signaling pathway for inflammatory 
cellular responses, which was the justification for using parthenolide as a possible 




cytoplasm. To keep NF-κB from entering into the nucleus and activating DNA, IκB 
is bound to NF-κB. When inflammatory signals stimulate cells, such as macrophages, 
IκB is phosphorylated by IκB kinase complex (IKC) ultimately causing the 
disassociation between NF-κB and IκB, allowing NF-κB to enter the nucleus. IKC is 
composed of three subunits: IKC-α, IKC-β, and IKC-γ. Parthenolide is believed to 
inhibit the IKC-β subunit (Kwok et al. 2001), leading to the inactivation of IKC 
thereby preventing NF-κB from entering the nucleus and activating DNA associated 
with and inflammatory response (Hehner et al. 1999). 
 
Figure 41. Parthenolide (pub med) 
To determine if parthenolide would be a good candidate as a drug to 
incorporate into alginate for the mitigation of NO production by macrophages, free 
parthenolide in solution was first tested over a variety of conditions. Our previous 
experiments presented in this thesis have shown that even highly purified 
pharmaceutical grade alginate can cause a significant increase in NO2 levels when in 
the presence of IFN-γ. Incorporating an anti-inflammatory drug into the alginate that 
has no effect on islet function could potentially extend the life span of an in vivo graft 
by retarding the initial inflammatory response upon implantation of the graft.  
A dose curve of parthenolide was tested under a range of LPS stimuli. The 




contamination (0.6 EU/mL LPS), and high contamination (6 EU/mL LPS). The same 
experiment was then repeated in the presence of IFN-γ. Once the potency of 
parthenolide was confirmed it was then incorporated into 2% w/v alginate beads and 
then same experiments were repeated. 
 
5.3.2 Experimental Design 
The parthenolide dose curve was made by serial dilution of 20 mM 
parthenolide (dissolved in DMSO) into CM. All other reagents were prepared as 
described in Chapter 3. Figure 42 is a schematic of the 96-well plate set up with a 
dose curve of parthenolide for each concentration of LPS. The DAN assay procedure 
was used to assess NO2 concentration over 20 and 24 h. 
 The production of “spiked” Pronova beads with parthenolide was performed 
by serial dilution using liquid alginate (2 % w/v). The solution was passed through 
the encapsulator with the following settings: 15 mL/hr, 0.35 mm OD needle, 6.5 KV. 
The beads were incubated in a 50 mM CaCl2 and 200 mM mannitol solution for 30 
mins. Mannitol serves as an osmalyte, regulating osmotic pressure. The beads were 
washed three times to remove excess CaCl2 after incubation period. The beads were 
stored in an equimolar CM solution containing parthenolide to limit any potential 
parthenolide from leaching out. Before use, the beads were washed three times with 
CM to remove any excess drug. The excess solution was removed to give packed 
beads and 40 μL aliquots were delivered to the plate (Fig. 43). An aliquot of 6 




a potential immune response. The NO2 concentrations were measured at 20, 24, and 
48 h with the DAN assay. 







Figure 42. Schematic of 96-well Plate for Free Parthenolide Dose Curve with a 
Simultaneous LPS Dose Curve +/- IFN-γ (n=4 per condition). 








Figure 43. Schematic of 96-well Plate for Incorporated Parthenolide In 2% w/v 






5.3.3 Free Parthenolide +/-LPS +/- IFN-γ Results 
The use of parthenolide free in solution was used to test the inhibitory action 
of the drug on RAW. Therefore, only two time points, 20 and 24 h, and three doses 
(none to strong) were tested. Each graph represents only one time point. The media 
values were pooled from two previous experiments as a comparison tool since space 
on the plate was limited. LPS controls in the absence of parthenolide are present. As 
the concentration of LPS increases, in the absence of parthenolide, the NO2 
concentration increases in the same manner as seen in Chapter 3 confirming that 
RAW is reacting in the normal manner to LPS stimulation. In the absence of LPS, at 
20 and 24 h (Figs. 44 & 45), parthenolide at all concentrations cause a significant 
decrease in NO2 when compared to the control (RAW only). This confirms that 
parthenolide is an inhibitor of NO production by RAW264.7 
Parthenolide was also tested in the presence of differing strengths of LPS to 
determine if parthenolide was a potent inhibitory of LPS-induced NO production. As 
LPS increased so did the NO2 levels. At each dose of LPS, increasing the 
concentration of parthenolide caused a corresponding decrease in NO2. These trends 
continued over time. At the highest concentration of parthenolide (5 μM), with the 
exception of 6 EU/mL LPS at 24 h (Fig. 45), the NO2 level is either significantly 
lower then the RAW control or at the same level. This indicates that parthenolide, at 5 
μM, can cause RAW cells, even in the presence of 6 EU/mL LPS, to not produce NO 




 At 24 h in the absence of LPS and parthenolide, the typical morphology 
(rounded appearance) and cell number of RAW24.7 were present. As the amount of 
parthenolide increased, RAW cell numbers decreased with the most dramatic 
reduction at 5 μΜ parthenolide. With the addition of LPS, in the absence of 
parthenolide, the RAW cells flatten out indicating typical differentiation with 
concomitant production of NO. However, as the parthenolide concentration increases, 
the cell number decreases indicating the cessation of RAW proliferation. Regardless 
of the exact mechanism of inhibition (decrease in proliferation, differentiation, 
cytotoxcity, or signaling pathway inhibition), parthenolide free in solution caused a 















Free Parthenolide +  Free LPS
Medium Only
RAW264.7 Only
 0 EU/mL LPS 0.6 EU/mL LPS 6 EU/mL LPS
 
Figure 44. Parthenolide with LPS Dose Curves In the Absence of IFN-γ. Overall, 




















Free Parthenolide + Free LPS
Medium Only
RAW264.7 Only
 0 EU/mL  LPS 0.6EU/mL LPS 6 EU/mL LPS
 
Figure 45.  Parthenolide and LPS Super-imposed Dose Curves Free In Solution In 
the Absence of IFN-γ at 24 h. The same trends as at 20 h are seen at 24 h with the 
exception that overall NO2 increases with increasing time. 
 
 With the addition of IFN−γ, there are now two stimuli present to increase NO 
production by RAW. Parthenolide was tested in the presence of these two stimuli to 
establish if parthenolide could cause the same dramatic decrease in NO2 as above 
(Fig. 46 & 47). In the absence of parthenolide, the NO2 concentration increased in an 
expected manner when LPS and IFN-γ were present. This indicated that the 
RAWcells were reacting in the normal, synergistic fashion to IFN-γ and increasing 
LPS.  IFN-γ caused a greater increase in NO2 and amplifies the effects of 
parthenolide. In the presence of IFN-γ in the absence of LPS, even a nanomolar 
concentration of parthenolide caused a significant decrease in NO2 (Fig. 46).  At each 




control. With the exception to exposure to 6 EU/mL LPS, even 1 μM parthenolide 
caused a significant decrease in NO2. 
Morphologically, in the presence of IFN-γ and the absence of parthenolide 
and LPS, the cells become bigger and flatter. In the presence of parthenolide alone as 
the concentration increased, the RAW cells become more speckled in appearance and 
decreased in number. When LPS was added to the parthenolide and interferon, the 
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Figure 46. Parthenolide and LPS Curves Free In Solution Super-imposed Dose In 
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Figure 47. Parthenolide and LPS Free In Solution Super-imposed Dose Curves In 
the Presence of IFN-γ at 24 h.   
 
5.3.4 Parthenolide Incorporated in 2% w/v Alginate +/-LPS +/-
IFN-γ Results 
 Following the observation that free parthenolide significantly decreased NO2 
levels, even in the presence of LPS and IFN−γ, parthenolide was incorporated into 
2% w/v alginate. Parthenolide-containing beads were dropped onto RAW +/- LPS, 
+/- IFN-γ, and NO2 was measured at 20, 24, and 48 h. In Chapter 3, we demonstrated 
that five times the amount of LPS needed to be incorporated into alginate to give a 
similar NO response to free LPS. In a similar fashion, this next set of experiments 
demonstrated that up to forty times the amount of parthenolide needed to be 




response as was seen with free parthenolide. RAW was only tested, in this series of 
experiments, in the presence of a maximal LPS (6 EU/mL) concentration which was 
free in solution. 
In the absence of LPS and IFN-γ (Fig. 48), RAW cells produced very little 
NO2, as expected (Fig. 48). Parthenolide in beads did not change this unstimulated, 
background level of NO. With the addition of LPS, there was a significant increase in 
NO2, indicating that RAW was reacting to LPS. Over time, the LPS-induced NO2 
increased. A striking reduction in NO2 was observed for the two highest 
concentration of parthenolide in the alginate beads (100 and 200 μM) at both 20 and 
24 h time points as compared to the control of RAW stimulated with only 6 EU/mL. 
At 20 h, even 10 μM incorporated parthenolide caused a significant decrease in NO2. 
However at 48 h, the inhibition by encapsulated parthenolide was overwhelmed. No 
reduction in NO2 concentration occurred in response to parthenolide-containing 
beads. Thus the inhibitory effect by encapsulated parthenolide on RAW264.7-
produced inflammation was time and degree of severity dependent. When 
inflammation was induce by IFN-γ only (Fig. 52), the inhibitory effect of 
parthenolide –incorporated beads on the RAW –produced inflammation was 
completely lost. This again demonstrated dependence of the inhibition and 
inflammation by parthenolide-incorporated beads on the severity of the inflammation 
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Figure 48. Inhibition of NO Production by Parthenolide Incorporated Into 2% w/v 
Alginate Beads (400 μm In Diameter) In the Absence of LPS and IFN-γ. There is 










Figure 49. Comparison of Incorporated Parthenolide Into 2% w/v Alginate Beads 
(400 μm In Diameter) On Top of RAW264.7 with No LPS and No IFN-γ at 20 and 
48 h. A) RAW at 20 h with 2% w/v alginate Beads with 0 μM parthenolide 
incorporated no LPS and no IFN-γ present. B) RAW at 20 h with 2% w/v alginate 
beads with 200 μM incorporated parthenolide no LPS and no IFN-γ present. C) RAW 
at 48 h with 2% w/v alginate beads with 200 μM parthenolide incorporated no LPS 
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Figure 50. Inhibition of NO Production by Parthenolide Incorporated Into 2% w/v 
Alginate Beads (400 μm In Diameter) In the Presence of LPS and Absence of IFN-







Figure 51. RAW264.7 Comparison of Incorporated Parthenolide Beads (400μm In 
Diameter) at 20 and 48 h with 6 EU/mL LPS. A)  RAW at 20 h with  0 μM 
Parthenolide 2% w/v, 6 EU/mL LPS and no IFN-γ present. B). RAW at 20 h with 200 
μM Parthenolide incorporated 2% w/v alginate beads, 6 EU/mL LPS and no IFN-γ 
present. C) RAW at 48 h with200 μM Parthenolide 2% w/v alginate beads, 6 EU/mL 
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Figure 52. Inhibition of NO Production by Parthenolide Incorporated Into 2% w/v 
Alginate Beads (400 μm In Diameter) In the Presence of IFN-γ and No LPS. There 






Figure 53. RAW264.7 Comparison of Incorporated 200 μM Parthenolide 2% w/v 








 In the presence of IFN-γ (Fig. 53), RAW cells begins to appear to be flattened 
in appearance at 20 h even in the presence of beads with 200 μM parthenolide. At 48 
h, debris is present and fewer RAW cells. The RAW cells that are present have 
flattened out and there are very few RAW cells still round in appearance.  
However, when IFN-γ was present with LPS (Fig. 54) at every time point the 
inhibition effect of parthenolide incorporated into the beads was again evident. 
Parthenolide incorporated into alginate decreased NO2 levels at the highest doses of 
parthenolide at 20 and 24 h. At 48 h though, again the parthenolide inhibition is 
overruled. At low levels of parthenolide (10 μM) there was a stimulatory effect with a 
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Figure 54. Inhibition of NO Production by Parthenolide Incorporated Into 2% w/v 








Figure 55. Comparison of RAW264.7 with Incorporated Parthenolide 2% w/v 
Alginate Beads (400 μm In Diameter) with LPS and IFN-γ. A) 20 h with 0 μM 
parthenolide. B) 48 h with 0 μM parthenolide. C) 20 h with 200 μM parthenolide 
 
 RAW in the presence of LPS and IFN-γ at 20 h, but 0 μM parthenolide beads 
(Fig. 55 A), exhibited the expected morphology as in Ch 3; in which the RAW cells 
are flattened over the surface of the well. At 48 h (Fig. 55 B), there was a lot of debris 
and very few RAW cells. At 20 h (Fig. 55 C), RAW, with 200 μM parthenolide 






5.4 Discussion and Conclusions 
Three drugs were tested for the mitigation of NO production of RAW by 
being incorporated into alginate beads.  Out of the three drugs, parthenolide was 
successful in terminating NO production. The bisphosphonates, clondronate and 
alendronate, have been reputed in some papers to cause macrophage apoptosis but in 
our hands caused little change to NO production by RAW. One published study used 
clondronate as a peritoneal cavity wash to eliminate any macrophages present before 
encapsulated rat islets were implanted (Omer et al. 2003). Alendronate was originally 
chosen as a negative control. In the literature, alendronate supposedly had no effect 
on macrophages or was slightly stimulatory (Makkonen et al. 1999). However, after 
observing the small inhibitory effect seen in this thesis by alendronate further 
literature searches brought to light some evidence that alendronate can cause 
macrophage apoptosis.  
 In our lab, little evidence was found to support using clondronate or 
alendronate free in solution in decreasing NO production. Since published reports 
indicate the increased efficacy of bisphosphonates incorporated into liposomes to 
protect them from being prematurely hydrolyzed in solution and encourage 
phagocytosis of drug (Monkkonen et al. 1994). This technique is called the 
“macrophage ‘suicide’ technique” and was developed by Van Roojen et al. which we 
attempted to replicate this methodology. The procedure requires a roto vap which Dr. 
DeShong at University of Maryland Chemistry Department kindly provided to me. 
According to the published reports about 1 % of the drug is actually incorporated into 




replication was terminated, given the non-sterile conditions of making the liposomes, 
the expense of the drugs, and the difficulty of obtaining significant concentration of 
encapsulated drugs precluded proceeding. Also, there was concern about the integrity 
of the liposome once incorporated into viscous alginate. 
 Parthenolide, on the other hand, was readily incorporated into our alginate 
beads, and did apparently decrease NO production, through inducing apoptosis of 
RAW. An ideal drug for incorporation into alginate would have to be non-toxic to 
islets at the concentration used. When parthenolide was present free in solution along 
with LPS and/or IFN-γ there was a dramatic decrease in NO2; sometimes much less 
NO2 compared to the control. Concomitant observations of cell morphology and 
number suggested that the parthenolide caused apoptosis of RAW in a dose 
dependent manner. Free parthenolide was capable of decreasing NO2 at nanomolar 
concentrations.  
With this evidence in hand, parthenolide was then incorporated into 2% w/v 
alginate beads which were then dropped onto RAW cells in culture. The highest 
possible concentration that we could be incorporate in alginate was 200 μM 
parthenolide. A dose curve of contamination then was done down to 10 μM 
parthenolide. While the results of decreasing NO2 were not as dramatic as 
parthenolide free in solution, the observed decreases demonstrates  promise for using 
Parthenolide, or some other similar acting drug, or an anti-inflammatory incorporated 
directly into microcapsules for inhibiting the initial inflammatory response occurring 
upon graft implantation. Pharmaceutical grade alginate contains LPS contamination 




Macrophages that are stimulated can produce high, sustained levels of NO that easily 
diffused through alginate causing islets to cease functioning. Using a drug like 
parthenolide to decrease the number of macrophages at the graft site could increase 
the lifespan of encapsulated islets by decreasing the overall level of NO. However, 
the inhibition effects were observed only at a relatively high concentration of 
parthenolide in the alginate, due to the sequestrating effect of the alginate gel and 
might limit the usefulness of this approach if islets are even slightly sensitive to the 
incorporated drug. Also, the inhibitory effects were only noted at early time points 
when a weak inflammatory response was present. Longer time of incubation when 
stronger NO responses were observed overwhelmed the inhibitory ability of 
incorporated parthenolide. Thus this adjunct to encapsulated cell therapy should be 
expected to be dependent on the intensity of inflammation induced by implantation, 





Chapter 6:  Overall Conclusions and Discussion 
 
6.1 Introduction 
The aim of this thesis was to define conditions under which cell-encapsulating 
alginate microspheres may trigger hazardous NO production by macrophages. 
Pursuant of that goal, the in vitro RAW264.7/DAN assay was used to detect LPS 
contamination under a variety of defined circumstances. The thesis looked at different 
factors that could affect the production of NO by RAW cells in response to alginate 
microspheres. These factors included: 1) the contamination of ubiquitous LPS present 
in the biomaterial; 2) bead diameter and bead delivery volume; and 3) the presence of 
anti-inflammatory drugs in the biomaterial. 
Two different classes of drugs were investigated as possible agents to mitigate 
NO production. Bisphosphonates are currently used in the treatment of osteoporosis 
and other inflammatory disease. Since macrophages come from the same origins as 
osteoclasts and have similar functions, this seemed to be a promising drug. 
Parthenolide which has been used for centuries in herbal medicine as an anti 
inflammatory is another drug that was studied. This drug was chosen from past 
experience in our lab as a potent inhibitor of NO production by RAW cells for which 




6.2 LPS Stimulation of RAW264.7 +/- IFN-γ 
Pharmaceutical grade alginate contains minute amounts of LPS (< 100 EU/g).  
Current purification methods cannot completely remove all traces of LPS in alginate. 
As a result, there is some concern that the alginate itself, due to the contamination, 
stimulates an immune response. This limits the applicability and lifespan of the graft 
with encapsulated islets. Acceptable levels of LPS contamination need to be defined 
for pharmaceutical grade alginate that will not instigate a significant immune 
response. 
 
6.2.1 Free LPS Stimulation of RAW264.7 +/- IFN-γ 
Our model macrophage cell line, RAW264.7, responded very well and in a 
dose dependent manner to LPS free in the cell growth medium. The NO2 levels in the 
growth medium, which are proportional to NO production, increased with increasing 
LPS concentration. Also, over time the NO2 levels increased for each LPS 
concentration up to 48 h. These results indicate that RAW response to LPS with 
sustained NO production similar for native macrophages. The DAN assay provided 
an effective and sensitive means of detecting NO2 and could be used to detect the 
NOEL and LOEL levels of free LPS in solution. Overall, in the absence of INF-γ, the 
NOEL of LPS on RAW can be detected down to 0.006 EU/mL and the LOEL to 
0.018 EU/mL. 
 IFN-γ is a cytokine produced by different cell types involved in the innate 
immune system, including macrophages. The cytokine was added to simulate a more 




NOEL and LOEL values. For LPS free in the growth medium stimulating RAW in 




6.2.2 Stimulation of RAW264.7 +/-IFN-γ by 2% w/v Pronova 
Alginate Contaminated with Defined Concentration of LPS 
An electrostatic encapsulator was used to create 2% w/v beads containing 
different amounts of LPS. The beads were used to simulate how an implanted graft 
would come into contact with immune cell types like macrophages. 
Since LPS is one of the most ubiquitous contaminates in alginate and the other 
biomaterials, the most difficult to remove, it is important to determine levels of LPS 
in alginate that do not produce a significant increase in NO production by 
macrophages. LPS was added to 2% w/v highly purified alginate (<100 EU/g LPS) in 
defined quantities and the NO response by RAW was measured. At 20 h, in some 
experiments even 2% w/v Pronova alginate with no exogenously added LPS 
produced a significant, though small, amount of NO. As time increased so did the NO 
response observed to adulterated alginate, with shifts in the observed NOEL’s and 
LOEL’s. In the presence of IFN-γ, there was a synergistic increase in NO production 
by RAW when the cells were in the presence of beads “spiked” with LPS compared 
to when no IFN-γ was present.  
 In all of the assays, increasing LPS contamination in alginate caused a 
corresponding increase in NO. However, about five times the concentration of LPS 




LPS present in the medium, to yield comparable NO2 levels. This indicates that 
assays using free LPS to determine acceptable NOEL and LOEL values for alginate 
are incomplete and inaccurate since much higher quantities of LPS are being 
sequestered in the alginate. These results also suggest tat even though inflammation 
can be triggered in complex immune reactions stimulated by external low levels of 
endotoxin, higher levels of endogenous LPS in biomaterials may be tolerated than 
free LPS studies might indicate. 
6.3 The Effect of Bead Size on NO Production +/- IFN-γ 
Besides LPS Contamination, other factors could instigate NO production in 
response to alginate such as beads-cell surface effects. These were studied in the form 
of exposing RAW cells to beads of defined diameter and volumes. The logic being 
that beads of smaller diameter would cover more of the bottom of the well; having 
more surface contact with the RAW cells. The goal was to obtain a monolayer of 
defined diameters beads, though using the same delivery volume of beads proved 
ineffectual. Beads of small diameter tended to form multiple layers at the bottom of 
the well while wells that were to contain larger beads sometimes had one bead or no 
beads at all. Therefore, different delivery volumes were employed for different sized 
beads to obtain a monolayer at the bottom of the well. Beads of a smaller diameter 
had a smaller delivery volume while beads of a larger diameter had a larger delivery 
volume to form monolayers on the adhered RAW cells. The appropriate volumes 
were determined by trial and error. The lowest volume used was 10 μL corresponding 




 In the absence of IFN-γ, having a lower aliquot volume of bead delivery did 
not correspond to lesser NO production as one might expect. This was due to the fact 
that there were many more beads in the bottom of the well having more contact with 
the RAW cells.  
Since all of the bead diameters lots were contaminated with the same 
concentration of exogenously-added LPS it could be that with the delivery of the 
beads more LPS was contacting the RAW cells, instigating more NO production. 
Beads of smaller diameter have maximal contact with the alginate. This was 
confirmed by the fact that beads of approximately 1000 μm in diameter, though 
containing the same concentration of LPS as smaller beads, did not cause a significant 
increase in NO2 compared to the control. Smaller beads give more total LPS 
contamination per well causing an increase in NO2 indicating higher NO production 
either through direct contact or the LPS leaching out over time. This suggests that 
using larger beads in the encapsulation of islets might be less inflammatory. There 
has been much debate over the utility of larger beads versus smaller beads. Smaller 
beads offer better diffusion properties while larger beads give thicker alginate 
coverage and therefore protection from direct contact with immune cells. Further 
study needs to be performed to elucidate this problem. The grafts will be surrounded 
by tissue in humans and the effects of bead size might be irrelevant to inflammation. 
However, for the same concentration available to macrophages in tissue beds, per unit 
volume (as in the in vitro defined well volumes) a larger surface area might still result 




 In the presence of IFN-γ, though no NO trend was detected with changes in 
bead diameters, except for a dramatic increase in NO production that was consistently 
higher then the control. This demonstrates that whatever effect bead size may have on 
modulating the degree f LPS-induced inflammation, a more potent or complex 
immune reaction can quickly swamp that effect. Since IFN-γ is known to be a potent, 
synergistic cytokine, even though the beads have a range of sizes and therefore there 
are theoretical differences in the amount of LPS available to the macrophages, in the 
presence of IFN-γ this is sufficient to stimulate maximal reactivity. 
6.4 Incorporation of Anti-Phagocytic Drugs Directly into 
Alginate Microspheres 
The concept of incorporating drugs into medical devices to fend off 
inflammatory reactions and thereby increase the lifespan and effectiveness of the 
device is already in commercial applications. For example, drug eluting stents are 
coated with anti-inflammatory drugs that leach out over time, preventing scar tissue 
overgrowth leading to reblockage of the artery at the location of the stent. This same 
technique might be applied to alginate or other biomaterials when encapsulating 
sensitive donor tissue such as islets. A drug might be incorporated into the alginate 
that either kills off the surrounding macrophages or severely mitigates the production 
of NO while having no or little effect on islet function. Also, an ideal drug would be 
one that works at very low concentrations such as in the nanomolar to low 






Bisphosphonate are used in the treatment of a variety of bone diseases. 
Osteoporosis is the most well known disease where bisphosphonates are used. Since 
osteoclasts and macrophages have the same cellular origin and similar phagocytic 
activity, bisphosphonates were considered a promising candidate for an anti-
inflammatory to be incorporated into alginate in this study.   
As an initial study, free alendronate and clondronate were test for reduction of 
RAW NO reactivity in the presence of LPS +/- IFN-γ. Both drugs free in solution had 
little effect on NO production by RAW cells in the presence of LPS +/-IFN-γ. Since 
some published studies indicates that bisphosphonates may require entrapments in 
liposomes for maximal activity in inhibiting macrophages, we did make an effort to 
test this methodology. 
We confirmed literature reports that this technique is far from perfect in that a 
very low percentage of the drug is actually incorporated into liposomes, much of the 
material used does not form into liposomes, there are problems in recovery of unused 
bisphosphonate and determination of the actual bisphosphonate concentration, it is 
nontrivial to remove empty of liposomes, and a slew of other problems exist.  
One of the main concerns in our lab was guaranteeing sterility of the drug. 
The procedure described by van Roojen et al. calls for using chloroform and a roto 
vap. However, this type of apparatus is not easily sterilized. Given the extreme 
sensitivity of our assay, difficulty in obtaining a significant concentration of 








The other anti-inflammatory drug studied in reagents to be incorporated into 
the alginate gel was parthenolide, a potent inhibitor of the main intracellular signaling 
pathway for inflammation, the NF-κB pathway. Parthenolide has been commonly 
used for centuries in herbal remedies for fevers and other inflammatory aliments. 
Parthenolide was first tested with RAW stimulated by LPS +/- IFN-γ free in solution. 
Parthenolide was observed to greatly decrease NO2 levels at low concentrations. 
 The effectiveness of parthenolide was tested under a number of conditions and 
stimuli. First, a dose curve of parthenolide was tested against a dose curve of free 
LPS to determine if parthenolide could overcome the stimulation of RAW by LPS +/- 
IFN-γ. In fact 5 μM parthenolide solutions severely decreased LPS-stimulated NO2 
levels by at least 50% even in the presence of IFN-γ. Increasing LPS, time, and the 
presence of IFN-γ caused an increase in NO2 levels. However, in all cases 5 μM 
caused almost complete inhibition of NO production. 
 The decision to use up to forty times more parthenolide in the alginate was 
based on our experience with LPS sequestered in alginate. Much more LPS 
incorporated into alginate was necessary to illicit a similar NO response as free LPS. 
The highest concentration of drug that could be incorporated into the gel was 200 




There were four conditions that were tested: No LPS/IFN-γ, No LPS but IFN-
γ, No IFN−γ but LPS, and LPS with IFN-γ.  In the case of no LPS and No IFN-γ, 
there was sight amount of NO production over time but as seen in previous 
experiments, RAW does not produce very much NO if unstimulated. With LPS to 
stimulate the RAW cells, there was a decrease in NO2 with the 100 and 200 μM 
doses. The highest dose, 200 μM, caused the greatest decrease of NO by more then 
50% compared to the control at 20 and 24 h.  At 48 h, the highest dose of 
parthenolide, even in the presence of LPS, NO production was no higher than the 
control (unstimulated RAW) (Fig. 50). With IFN-γ as the only stimulator, there was a 
decrease in NO2 by parthenolide-containing microcapsules, but not as dramatic as the 
case of only LPS. With both inflammatory stimulators, working together in a potent 
synergistic fashion, parthenolide caused a decrease of NO to control levels at 20 and 
24 h. At 48 h, NO production in the presence of parthenolide did rise above the 
control level but compared to the control, possibly indicating that the LPS and IFN-γ 
given enough time can override the opposing parthenolide effect. 
These data show that parthenolide or other anti-inflammatory drugs might be 
incorporated into alginate to prolong function of implanted tissue-engineered grafts. 
In the case of parthenolide, further studies would have to be done to confirm that has 
no effect on islet function, as some of the literature indicates. If successful, 
incorporation of anti-phagocytic drugs, like parthenolide, into alginate might be one 






In conclusion, the data of this thesis suggest that : 1) the effectiveness of the 
RAW264.7/DAN assay can be very efficient in detecting LPS contamination at very 
low levels; 2) NOEL and LOEL concentrations for endotoxin contamination in 
pharmaceutical grade alginate are much lower then previously thought, particularly 
when IFN-γ is present; 3) correspondence of inflammation in patients implanted with 
biomaterial containing devices may be dependent upon the preexisting inflammatory 
state of the patient both systematically and at the site of implantation; 4) the 
bioavailability of endotoxin when contained within alginate microcapsules in the 
presence or absence of a T-cell mediator IFN-γ is decreased versus free endotoxin; 
suggests that an implanted device could safely contain more LPS then suggested by 
free LPS results; 5) the inflammatory effect by LPS-contaminated biomaterials is 
related to the amount of surface area exposed to tissues; though a strong pre-existing 
immune response may swamp any surface area-mitigating effects; and 6) possible 
modulating physical agents, like anti-phagocytic drugs such as parthenolide, may be 
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